

SAHCS
GUIDELINES



SOUTHERN AFRICAN HIV CLINICIANS SOCIETY
GUIDELINES FOR ANTIRETROVIRAL THERAPY
IN ADULTS: **2020 UPDATE**



SOUTHERN AFRICAN HIV CLINICIANS SOCIETY GUIDELINES FOR ANTIRETROVIRAL THERAPY IN ADULTS: 2020 UPDATE

Authors: Jeremy Nel, Siphon Dlamini, Graeme Meintjes (*Chairpersons*), John Black, Rosie Burton, Natasha Davies, Eric Hefer, Gary Maartens, Pheto Mangena, Moeketsi Mathe, Mahomed-Yunus Moosa, Muhanwi Mulaudzi, Michelle Moorhouse, Jennifer Nash, Thandekile Nkonyane, Wolfgang Preiser, Mohammed Rassool, David Stead, Helen van der Plas, Cloete van Vuuren, Francois Venter, Joana Woods

Affiliation: Southern African HIV Clinicians Society

Corresponding author: [Jeremy Nel](#)

Disclaimer: Specific recommendations provided here are intended only as a guide to clinical management, based on expert consensus and best current evidence. Treatment decisions for patients should be made by their responsible clinicians, with due consideration for individual circumstances. The most current version of this document should always be consulted.

License: This guideline is licensed under the [Creative Commons CC BY-NC-ND 4.0](#) license. Licensee: Southern African HIV Clinicians Society.

How to cite: Nel J, Dlamini S, Meintjes G, *et al.*; for the South African HIV Clinicians Society. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. *Southern African Journal of HIV Medicine* 2020;21(1), a1115. <https://sahivsoc.org/ARTGuidelines>

Competing interests: The authors have declared that no competing interests exist.

Digital format: These guidelines are also available in digital format at <https://sahivsoc.org/ARTGuidelines>.



TABLE OF CONTENTS

What's new in the 2020 guidelines update?	4
Abbreviations	5
1.  Preamble	6
2.  Nucleoside/nucleotide reverse transcriptase inhibitor class of antiretroviral drugs	7
3.  Integrase strand transfer inhibitor class of antiretroviral drugs	11
4.  Non-nucleoside reverse transcriptase inhibitor class of antiretroviral drugs	14
5.  Protease inhibitor class of antiretroviral drugs	17
6.  Initiation and timing for antiretroviral therapy	19
7.  Baseline investigations	23
8.  Viral load	24
9.  CD4 ⁺ cell count	26
10.  Resistance and genotyping	28
11.  Initial antiretroviral therapy regimens for the previously untreated patient	32
12.  Management of patients currently receiving first-line therapy	34
13.  Management of patients starting or currently receiving second-line therapy	37
14.  Third-line antiretroviral therapy	40
15.  Laboratory monitoring of the efficacy and safety of antiretroviral therapy	43
16.  Patients who return after stopping antiretroviral therapy	44
17.  Drug-drug interactions	46
18.  Tuberculosis	48
19.  Pregnancy and breastfeeding	51
20.  Liver disease	54
21.  Renal disease	56
22.  Psychiatric disease	58
23.  Malaria	59
24.  Antiretroviral drug-induced liver injury	61
25.  Dyslipidaemia	63
26.  Immune reconstitution inflammatory syndrome	65
27.  Opportunistic infection prophylaxis	67
28.  Adherence	69
29.  Useful algorithms and summaries	72
References	84

WHAT'S NEW IN THE 2020 GUIDELINES UPDATE?

Key updates

- A recommendation for dolutegravir (DTG)-based therapies as the preferred first-line antiretroviral therapy (ART) option ([Module 11](#))
- Updated guidelines for second- and third-line ART ([Module 13](#))
- New recommendations on the management of patients on DTG-based therapies who have an elevated viral load (VL) ([Module 12](#))
- A lowering of the threshold for virological failure from 1000 copies/mL to 50 copies/mL ([Module 8](#))
- A recommendation against routine CD4⁺ count monitoring in well patients once the CD4⁺ count > 200 cells/μL ([Module 9](#))
- Updated recommendations for isoniazid preventive therapy (IPT) in HIV-positive patients ([Module 27](#))
- A recommendation for the use of low-dose prednisone as prophylaxis for paradoxical tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS) in TB/HIV co-infected patients commencing ART within one month of TB therapy ([Module 26](#))

ABBREVIATIONS

/r	ritonavir-boosted	GI	gastrointestinal	PI	protease inhibitor
3TC	lamivudine	Hb	haemoglobin	PI/r	ritonavir-boosted protease inhibitor
ABC	abacavir	HBsAg	hepatitis B surface antigen	PMTCT	prevention of mother-to-child transmission of HIV
ADR	adverse drug reaction	HBV	hepatitis B virus	PPIs	proton pump inhibitors
AKI	acute kidney injury	HIV	human immunodeficiency virus	PrEP	pre-exposure prophylaxis
ALT	alanine transaminase	ICU	intensive care unit	QTc	corrected QT interval
ANC	antenatal care	INH	isoniazid	RAL	raltegravir
ART	antiretroviral therapy	INR	international normalised ratio	RCTs	randomised controlled trials
ARV	antiretroviral	InSTI	integrase strand transfer inhibitor	RIF	rifampicin
AST	aspartate transaminase	IPT	isoniazid preventive therapy	RFB	rifabutin
ATV	atazanavir	IRIS	immune reconstitution inflammatory syndrom	RNA	ribonucleic acid
ATV/r	ritonavir-boosted atazanavir	LAM	lipoarabinomannan	RPV	rilpivirine
AZT	zidovudine	LDL-C	low-density lipoprotein cholesterol	RTV or /r	ritonavir
bd	twice daily	LP	lumbar puncture	sCr	serum creatinine
CD4⁺	cluster of differentiation 4	LPV	lopinavir	sCrAg	serum cryptococcal antigen
CM	cryptococcal meningitis	LPV/r	ritonavir-boosted lopinavir	TAF	tenofovir alafenamide
CrAg	cryptococcal antigen	MDRD	modification of diet in renal disease	TAM	thymidine analogue mutation
CrCl	creatinine clearance rate	MTCT	mother-to-child transmission of HIV	TB	tuberculosis
CNS	central nervous system	MVC	maraviroc	TB-IRIS	tuberculosis immune reconstitution inflammatory syndrome
CSF	cerebrospinal fluid	NGT	nasogastric tube	TBM	tuberculosis meningitis
CTX	cotrimoxazole	NNRTI	non-nucleoside reverse transcriptase inhibitor	TC	total cholesterol
d4T	stavudine	NRTI	nucleoside reverse transcriptase inhibitor	TDF	tenofovir disoproxil fumarate
ddI	didanosine	NTDs	neural-tube defects	TG	triglycerides
DILI	drug-induced liver injury	NtRTI	nucleotide reverse transcriptase inhibitor	TST	tuberculin skin test
DNA	deoxyribonucleic acid	NVP	nevirapine	UDP	uridine 5'-diphospho
DRV	darunavir	OI	opportunistic infection	ULN	upper limit of normal
DRV/r	ritonavir-boosted darunavir	PAS	p-aminosalicylic acid	VL	viral load
DTG	dolutegravir	PCR	polymerase chain reaction	WHO	World Health Organization
eGFR	estimated glomerular filtration rate			WOCP	women of childbearing potential
ELISA	enzyme-linked immunosorbent assay				
ETR	etravirine				
FBC	full blood count				
FTC	emtricitabine				



PREAMBLE

Key principles

Although many antiretroviral therapy (ART) guidelines are available internationally, the current guidelines have been written to address issues relevant to southern Africa. A major spur for the current guidelines is the introduction of dolutegravir (DTG) into first- and second-line ART regimens. DTG-based ART regimens hold much promise, although the transition inevitably challenges existing paradigms and generates additional complexities. These guidelines aim to address many of these and to update the text in general to reflect the latest evidence.

As with previous iterations, these guidelines take affordability into account, as countries in the region vary between low- and middle-income countries. Hence, only the treatment and diagnostic options that are available in southern Africa are included. In addition, these guidelines recognise the need to bridge the gap in treatment recommendations between public and private sector programmes, considering that many patients transition between the two sectors for treatment. The format of this iteration of the guidelines has been modified to highlight each sections' **key points** and **common pitfalls**.

Goals of antiretroviral therapy

- Provide maximal and durable suppression of viral load.
- Restore and/or preserve immune function.
- Reduce HIV-related infectious and non-infectious morbidity.
- Prolong life expectancy and improve quality of life.
- Prevent onward transmission of HIV.
- Minimise adverse effects of the treatment.

These goals are achieved by suppressing viral replication completely for as long as possible, using well-tolerated and sustainable treatment taken with good adherence. With prolonged viral suppression, the

CD4⁺ lymphocyte count usually increases, which is accompanied by a restoration of pathogen-specific immune function. For most patients, this results in a dramatic reduction in the risk of HIV-associated morbidity and mortality. In patients who start to receive ART with preserved CD4⁺ counts, ART is able to prevent the decline in CD4⁺ count observed in untreated patients and prevent clinical complications of HIV infection. It is still unclear whether immune function ever returns to full normality, though long-term cohorts show that patients who adhere well to ART have a near-normal life expectancy.¹ Patient adherence to their ART regimen remains a key focus and challenge.

Stopping antiretroviral therapy

ART should not be stopped unless there is an extremely compelling reason to do so. In most cases where drug toxicities develop, switching the culprit drug(s) should be attempted instead. If non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy is stopped, then we generally do not recommend 'covering the tail' with an additional 5–7 days of nucleoside reverse transcriptase inhibitors (NRTIs). There is little evidence for this in patients on long-term ART, and the intracellular half-life of drugs such as tenofovir disoproxil fumarate (TDF), in any case approximates that of the NNRTIs.² It is important to ensure that the viral load (VL) is suppressed before substituting a single drug for toxicity, otherwise resistance may develop to the new drug, consequently compromising future regimens. However, single-drug substitutions can be done in the first few months of ART without measuring the VL, as the VL may take up to 6 months to become suppressed.

We strongly advise against lamivudine (3TC) monotherapy 'holding regimens' in patients who have virological failure. Such regimens can be associated with a rapid fall in CD4⁺ count. The objective when prescribing ART should always be to provide a regimen that is most likely to achieve virological suppression.



NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR CLASS OF ANTIRETROVIRAL DRUGS

Key points

- The recommended nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) drugs for first-line therapy are tenofovir disoproxil fumarate (TDF) and either lamivudine (3TC) or emtricitabine (FTC).
- Patients with a creatinine clearance rate (CrCl) < 50 mL/min should generally be started on abacavir (ABC) instead of TDF for first-line therapy.
- Zidovudine (AZT) should only be used in special circumstances as a first-line drug.
- TDF can cause renal failure or a renal-tubular wasting syndrome. Creatinine monitoring at regular intervals is recommended.
- ABC can cause a fatal hypersensitivity reaction in patients with HLA-B*5701. If feasible, this allele should be excluded prior to starting ABC, although it is very rare in people of African descent.
- AZT can cause anaemia and neutropenia, and regular monitoring of haemoglobin (Hb) and neutrophil count is recommended for the first 6 months.

Available nucleoside/nucleotide reverse transcriptase inhibitors

Nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) work by acting as nucleotide base analogues. Following incorporation into the DNA chain by HIV's reverse transcriptase enzyme, they block further chain elongation. A summary of NRTIs is provided in [Table 1](#), and the appropriate baseline investigations and required monitoring are presented in [Table 2](#). NRTIs may be available as single tablets or in fixed-dose combination (FDC). The latter is recommended where possible to decrease the overall pill burden. Many NRTIs require dose adjustment in renal failure (see [Module 21](#)).

Lamivudine and emtricitabine

Lamivudine (3TC) and emtricitabine (FTC) are well-tolerated drugs recommended as part of a first-line regimen. Although there are minor differences between them, 3TC and FTC are considered functionally interchangeable. Their use may be continued in the presence of 'high-level resistance' caused by the M184V mutation, since this mutation impairs HIV's replication ability, causing a ~0.5 log decrease in VL. Therefore, the drugs are often used in second- and third-line therapies (see the management of patients on second-line ART in [Module 13](#)). 3TC and FTC are active against hepatitis B, but when used in the absence of a second

drug active against hepatitis B virus (HBV), such as TDF, resistance rates of approximately 50% at 1 year, and 90% at 5 years, are seen.³ See [Module 20](#).

Tenofovir disoproxil fumarate

Tenofovir disoproxil fumarate (TDF) is the preferred drug in this class for use with 3TC or FTC in first-line therapy because it aligns with public sector programmes, is widely available as an FDC, and is generally well-tolerated. TDF also offers durable therapy against HBV. HBV resistance against TDF is exceedingly rare. In a minority of patients, TDF may cause a tubular wasting syndrome (including wasting of phosphate and potassium).⁴ If patients receiving TDF develop muscle weakness or other muscle symptoms, then potassium and phosphate levels must be assessed. TDF can also cause acute and chronic renal failure, but this is uncommon.⁵

TDF should be switched to ABC or an alternative NRTI immediately in patients with acute renal failure, as it may exacerbate injury even if it is not the primary cause. Consider recommencing TDF with careful monitoring when the creatinine result is normal if an alternative cause of renal failure is established.

We recommend estimating the creatinine clearance rate (CrCl) before commencing TDF; the drug should not be used if the estimated glomerular filtration rate (eGFR) or CrCl is < 50 mL/min. For monitoring while

TABLE 1: Dosage and common adverse drug reactions of nucleoside/nucleotide reverse transcriptase inhibitors available in southern Africa (adult dosing).

Generic name	Drug class	Recommended dosage	Common or severe ADR [‡]
Tenofovir disoproxil fumarate (TDF)	NtRTI	300 mg daily	Renal failure , tubular wasting syndrome, reduced bone mineral density, nausea
Lamivudine (3TC)	NRTI	150 mg 12-hourly or 300 mg daily	Anaemia (pure red cell aplasia) (rare)
Emtricitabine (FTC) [†]	NRTI	200 mg daily	Anaemia (pure red cell aplasia) (rare), palmar hyperpigmentation
Abacavir (ABC)	NRTI	300 mg 12-hourly or 600 mg daily	Hypersensitivity reaction
Zidovudine (AZT)	NRTI	300 mg 12-hourly	Anaemia, neutropenia , GI upset, headache, myopathy, hyperlactataemia/steatohepatitis (medium potential), lipodystrophy

ADR, adverse drug reaction; GI, gastrointestinal; NtRTI, nucleotide reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.

†, FTC is not available as a single drug in South Africa, only co-formulated.

‡, Life-threatening reactions are indicated in **bold**.

TABLE 2: Baseline investigations and monitoring required for nucleoside/nucleotide reverse transcriptase inhibitors.

Generic name	Monitoring required	Comment
TDF	Creatinine before initiation, then at 3 months, 6 months, and then 6-monthly thereafter	<ul style="list-style-type: none"> • Avoid if eGFR < 50 mL/min • In high-risk patients (particularly those with co-existent hypertension or diabetes), creatinine should also be checked at 1 and 2 months
3TC	None routinely required	-
FTC	None routinely required	-
ABC	HLA-B*5701 before initiation, if testing is affordable and available	• Allele very rare in people of African descent
AZT	Hb and neutrophil count before initiation, then at months 1, 2, 3 and 6	<ul style="list-style-type: none"> • Avoid if Hb < 8 g/dL • If neutrophil count is 1–1.5 × 10⁹, then repeat in 4 weeks • If neutrophil count is 0.75–0.99 × 10⁹, then repeat in 2 weeks or consider switching from AZT • If neutrophil count is < 0.75 × 10⁹, then switch from AZT.

3TC, lamivudine; ABC, abacavir; ADR, adverse drug reaction; AZT, zidovudine; eGFR, estimated glomerular filtration rate; FTC, emtricitabine; Hb, haemoglobin; TDF, tenofovir disoproxil fumarate.

on TDF see [Table 2](#). Where TDF is avoided because CrCl is < 50 mL/min at baseline, it may be possible to switch to TDF at a later point if renal function improves. This is often the case where patients had diarrhoea or other opportunistic infections (OIs) at the time of ART initiation.



Common pitfall: Permanently discontinuing TDF in patients with transiently decreased CrCl. Most cases of acute kidney injury (AKI) are not because of TDF, and if another cause of AKI is identified (e.g. severe diarrhoea or pneumonia), then TDF can be re-introduced with monitoring once renal function improves.

causes a decrease in bone mineral density; however, this is generally mild and non-progressive, and most studies have not found an increase in fracture risk.

Abacavir

Abacavir (ABC) can be used in patients with a CrCl < 50 mL/min at baseline, rather than TDF. ABC does not require dose adjustment in patients with renal failure and is especially useful in patients with chronic renal failure, where TDF is nephrotoxic and zidovudine (AZT) could aggravate the anaemia of renal failure. A meta-analysis showed that virological suppression is equivalent with ABC- and TDF-containing first-line regimens regardless of baseline VL.⁶



Common pitfall: Avoiding ABC at high HIV VLs. This is unnecessary, as viral suppression rates are equivalent in meta-analyses.

Long-term use of TDF together with other nephrotoxic agents (e.g. aminoglycosides or non-steroidal anti-inflammatory agents) should be avoided. TDF also



ABC has been associated with an increased risk of myocardial infarction in some but not all cohort studies; however, the association was not confirmed in a meta-analysis of randomised controlled trials (RCTs).^{6,8} Nevertheless, caution is recommended when considering ABC for patients who are at significant risk of, or have established ischaemic heart disease. ABC hypersensitivity is a systemic reaction occurring within the first 8 weeks of therapy in approximately 3% of cases. Fatalities may occur on rechallenge. **ABC must be discontinued and never re-introduced if hypersensitivity is suspected.** The manifestations of hypersensitivity include fever, rash, fatigue and abdominal or respiratory symptoms. If there is any doubt concerning the diagnosis (e.g. if the patient has a cough with fever), then the patient should be admitted for observation of the next dose;

symptoms progress if hypersensitivity is present. The hypersensitivity reaction has been shown to occur on a genetic basis, with a very strong association with the HLA-B*5701 allele. This allele is very uncommon in people of African descent; thus, ABC hypersensitivity is less frequent. If testing is affordable and available, then the presence of HLA-B*5701 should be excluded prior to prescribing ABC, especially in patients who are not of African descent.

Zidovudine

We now recommend reserving zidovudine (AZT) for use only in special circumstances in first-line therapy. If both TDF and ABC are unavailable or contra-indicated, then AZT should be used, provided that Hb is > 8 g/dL.

Additional syndromes related to nucleoside reverse transcriptase inhibitors

Haematological toxicity

Cytopenias occur commonly in HIV infection without exposure to ART. Patients receiving AZT or cotrimoxazole (CTX) may experience full blood count (FBC) abnormalities. AZT can cause anaemia and neutropenia; platelet counts generally rise with the use of the drug. Monitoring is necessary with AZT (see [Table 2](#)). It is unusual, however, to see haematological toxicity develop after 6 months. Macrocytosis is usual with AZT therapy and is of little consequence. Routine measurement of vitamin B12 and folate concentrations is not needed.



Common pitfall: Discontinuing AZT because of macrocytosis. This is of little consequence, and does not necessarily portend subsequent anaemia.

Pure red cell aplasia, which presents with severe anaemia and a low reticulocyte production index, has rarely been associated with 3TC and FTC.^{9,10} A bone marrow examination should be performed to confirm the condition. A polymerase chain reaction (PCR) test should be performed to exclude parvovirus B19 infection. If 3TC and FTC are contraindicated due to pure red cell aplasia, then we suggest contacting an expert for advice about alternative regimens.

Hyperlactataemia and lactic acidosis

Lactic acidosis is a rare but serious and potentially fatal side-effect of NRTIs, most commonly associated with stavudine (d4T), particularly when combined with didanosine (ddl). These drugs are no longer used. It can also occur occasionally with AZT. Symptomatic hyperlactataemia without acidosis is more common and is associated with the same drugs. Neither lactic acidosis nor hyperlactataemia without acidosis is seen with the newer, safer NRTIs such as TDF, ABC, 3TC or FTC.

Symptoms are non-specific and include nausea and vomiting, abdominal pain, dyspnoea, fatigue and weight loss. A raised lactate (> 5 mmol/L) together with metabolic acidosis confirms a diagnosis of lactic acidosis. Low serum bicarbonate (< 20 mmol/L) is the most sensitive marker of acidosis. Patients receiving AZT who develop hyperlactataemia should be switched to alternative drugs, and lactate monitored serially until resolution. In severe cases, admission may be required.

Lipoatrophy

The thymidine analogue NRTIs (AZT and especially d4T) are associated with subcutaneous fat loss (most noticeable in the face, limbs and buttocks). Lipoatrophy improves when d4T/AZT are substituted with TDF or ABC, but resolution is very slow and often incomplete; therefore, it is important to recognise lipoatrophy early or, better still, to use NRTIs that are not associated with the condition. Although d4T is no longer used, patients who received it historically may still have lipoatrophy.





INTEGRASE STRAND TRANSFER INHIBITOR CLASS OF ANTIRETROVIRAL DRUGS

Key points

- Two integrase strand transfer inhibitors (InSTIs) are available in southern Africa, namely dolutegravir (DTG) and raltegravir (RAL).
- DTG is preferred to RAL because it has a higher barrier to resistance, is available in FDC formulation, and can be taken once daily.
- DTG has been shown to have greater efficacy than efavirenz (EFV), driven largely by superior tolerability.
- DTG causes a small increase in serum creatinine (sCr) (usually 10–20 µmol/L) due to interference with tubular creatinine secretion; however, this does not represent a decline in renal function.
- Although definitive data are still lacking, DTG may be teratogenic in a small proportion of cases, thus treatment decisions in women of reproductive age should be discussed and evaluated carefully (see **Module 19**).
- Weight gain is a newly recognised side-effect of InSTIs, more so with DTG than with RAL, and more so in black women and in patients with lower baseline CD4⁺ counts and higher VLs.

Overview of integrase strand transfer inhibitors

Integrase strand transfer inhibitors (InSTIs) – often simply termed ‘integrase inhibitors’ – work by preventing the transfer of proviral DNA strands into the host chromosomal DNA. Currently, two InSTIs are available in southern Africa: dolutegravir (DTG) and raltegravir (RAL). DTG is preferred to RAL due to its higher barrier to resistance, its availability in FDC formulation, and the ability to take the drug once daily. The SPRING-2 trial compared DTG- and RAL-containing first-line regimens and found no significant differences in virological suppression, and adverse effects were similar between treatment groups;¹¹ however, although no patients in the DTG arm were found to have developed resistance, one patient in the RAL arm developed InSTI resistance and four developed NRTI resistance. The high barrier to resistance of DTG-containing ART regimens has been replicated in other first-line studies and in a study of ART-experienced patients in which DTG was compared to RAL.^{12–14} In a meta-analysis that included clinical trials and observational studies, the emergence of InSTI resistance was more common with RAL than with DTG (3.9% vs. 0.1%).¹⁵ However, the emergence of InSTI resistance in patients receiving RAL can compromise second-generation InSTIs such as DTG.

DTG use has been shown to be superior to EFV-based ART in the SINGLE trial.¹² This difference was largely

driven by the superior tolerability of the DTG arm: 2% vs. 10% in the EFV arm had an adverse event leading to discontinuation of the study drug. DTG showed superior rates of viral suppression (71% vs. 63% respectively at 144 weeks).

DTG-based regimens have also been shown to be superior to PI-based regimens. As first-line therapy, DTG was superior to DRV/r with respect to both viral suppression rates and side-effect profile.¹³ The ARIA trial of ART-naïve women demonstrated DTG’s non-inferiority to ATV/r, although with a statistically significantly higher rate of viral suppression and fewer side-effects overall.¹⁶ In the DAWNING trial considering second-line regimens, DTG was superior to LPV/r.¹⁷ Importantly, at least one fully active NRTI was genotypically confirmed at baseline in this trial.

Data from the Tsepamo surveillance study in Botswana demonstrated a statistically higher rate of neural-tube defects (NTDs) among women who were taking DTG at the time of conception (0.3% vs. 0.1% in women receiving other ART in the periconception period).¹⁸ Unlike in South Africa, folate fortification of staple foods does not occur in Botswana. In contrast to the Botswana data, no NTDs were reported in a Brazilian cohort of 1468 women, 382 of whom were DTG-exposed.¹⁹ Although additional data will undoubtedly be forthcoming, it should be noted that the absolute risk is < 0.5%, and this risk may be



outweighed by the additional benefits of DTG over alternative therapies. We recommend that women of childbearing potential (WOCP), particularly those who wish to become pregnant or who have no reliable access to effective contraception, should be counselled adequately about the potential risks and benefits of DTG- vs. EFV-based ART, and should be offered a choice of first-line regimens.

Common side-effects

DTG and RAL are generally well tolerated, with most side-effects being mild and very rarely leading to discontinuation. DTG may cause a mild increase in sCr

due to interference with tubular secretion. This does not represent renal damage and is not an indication for switching to another drug. The rise in sCr occurs within the first few weeks, and persists for as long as the patient remains on DTG.



Common pitfall: Assuming that the rise in sCr seen in patients on DTG necessarily represents renal failure. In reality, the effect of DTG on creatinine secretion is of no consequence and does not represent a decline in renal function.

RAL and DTG can cause headaches when started, but this usually resolves. These drugs may also cause insomnia and neuropsychiatric side-effects. RAL and DTG can occasionally cause hypersensitivity rashes, including life-threatening rashes. Weight gain is more pronounced in patients taking an InSTI as part of their ART regimen (with the exception of cabotegravir, which is not currently available in South Africa). Black women, patients with low baseline CD4⁺ counts, and patients with high baseline VLs appear to be at greatest risk.²⁰ The risk also appears to be moderated by the companion drugs in the patient's ART regimen. In the ADVANCE trial, women on a tenofovir alafenamide (TAF) + FTC + DTG regimen gained a median of 10 kg over 96 weeks, with little evidence of a plateau in the increase.²¹ In women, median weight gain in the same period in the TDF + FTC + DTG arm was 5 kg, and 3 kg in the TDF + FTC + EFV arm. In men, weight gain was approximately half as much in each arm. The long-term health implications of these findings are currently unclear, but clinicians should be aware of the possibility of weight gain, and encourage appropriate exercise and dietary measures to limit this.

Dosage and common adverse drug reactions (ADRs) of InSTIs are described in [Table 3](#).

TABLE 3: Dosage and common adverse drug reactions of integrase strand transfer inhibitors available in southern Africa.

Drug	Recommended dosage	Common or severe ADR
RAL	400 mg 12-hourly	Headache and other CNS side-effects, GI upset, hepatitis and rash (rare), rhabdomyolysis (rare). Weight gain.
DTG	50 mg daily	Insomnia, headache and other CNS side-effects, GI upset, hepatitis and rash (rare). Possibly teratogenic . Weight gain.

ADR, adverse drug reaction; CNS, central nervous system; DTG, dolutegravir; ETR, etravirine; GI, gastrointestinal; PI, protease inhibitor; RAL, raltegravir.

Key drug-drug interactions with dolutegravir

Key drug-drug interactions involving DTG are summarised in [Table 4](#).

TABLE 4: Key drug-drug interactions with dolutegravir.	
Drug	Action required
RIF	<ul style="list-style-type: none">Administer DTG twice-daily (i.e. 50 mg 12-hourly) until 2 weeks after stopping RIF.
Metformin	<ul style="list-style-type: none">Do not exceed metformin 500 mg 12-hourly.
Carbamazepine, phenytoin	<ul style="list-style-type: none">Give alternative anticonvulsant if possible (e.g. lamotrigine or topiramate).If carbamazepine is used, then administer DTG 12-hourly.Avoid phenytoin with DTG altogether.
Polyvalent cation-containing agents (e.g. antacids, laxatives, sucralfate, iron and calcium supplements).	<ul style="list-style-type: none">For magnesium-/aluminium-containing antacids, administer > 2 hours after or > 6 hours before DTG dose.For iron/calcium supplements, either take with food or apply intervals above.
Etravirine (ETR)	<ul style="list-style-type: none">Do not use DTG + ETR together unless a boosted PI is also used in the combination.

DTG, dolutegravir; ETR, etravirine; RIF, rifampicin, PI, protease inhibitor.



Common pitfall: Forgetting to dose DTG twice daily when rifampicin (RIF)-based tuberculosis (TB) treatment is commenced.





NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR CLASS OF ANTIRETROVIRAL DRUGS

Key points

- Efavirenz (EFV) remains a good first-line ART option for patients who tolerate DTG poorly, or where DTG is contraindicated or declined.
- EFV 400 mg is non-inferior to EFV 600 mg and offers a somewhat improved side-effect profile. However, it is currently not available in FDC, and has not been well studied in patients receiving rifampicin (RIF)-based TB treatment or in pregnant women.
- Rilpivirine (RPV) is another good first-line option, but it is not available in FDC, cannot be co-administered with RIF-based TB treatment, and should not be started in patients with a VL > 100 000 copies/mL.
- Nevirapine (NVP) is no longer recommended for new patients due to its adverse side-effect profile.
- Etravirine (ETR) may be used as part of third-line therapy where appropriate, but is not recommended as a first-line agent.

Non-nucleoside reverse transcriptase inhibitors

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) work by binding irreversibly to HIV's reverse transcriptase enzyme, which causes a conformational change in the enzyme's active site and impairs its functioning. The four NNRTIs currently available in southern Africa are efavirenz (EFV), nevirapine (NVP), rilpivirine (RPV) and etravirine (ETR).

Individual non-nucleoside reverse transcriptase inhibitors

Efavirenz

Efavirenz (EFV) is available in 600 mg and 400 mg formulations. EFV 600 mg is available in public sector programmes in most countries in southern Africa. There is extensive clinical experience with the formulation, and it is available in FDC. EFV 400 mg demonstrated non-inferior efficacy with moderately improved tolerability in the ENCORE1 study.²² However, there are only limited pharmacokinetics data in pregnant patients, and in patients receiving RIF-based TB treatment. EFV 400 mg is currently also not available in FDC. For these reasons, we do not recommend the routine use of EFV 400 mg in first-line ART. It remains an appropriate choice, however, in selected patients.

EFV frequently causes neuropsychiatric effects in the first few weeks of therapy, typically presenting with insomnia, vivid dreams and dizziness. Both dysphoria

and euphoria may occur. Patients starting EFV should be warned about these symptoms, and reassured that they resolve in most patients continuing the drug after the first few weeks, and if not, then an alternative can be substituted. Psychosis may occasionally occur. If the neuropsychiatric effects of EFV are not tolerated, then the patient should be switched to RPV, DTG or lower-dose EFV. Recently, a late-onset encephalopathy syndrome has been linked to EFV.²³



This is characterised by a subacute encephalopathy and cerebellar dysfunction, frequently presenting months to years after commencing EFV, and is associated with suprathreshold EFV levels. Patients who are genetically slow metabolisers of EFV may be predisposed to this syndrome. Two common CYP2B6 polymorphisms linked to slow EFV metabolism have been shown to occur with increased frequency in patients of African descent.²⁴ This predisposition to toxic EFV levels may be further exacerbated in patients of low body weight and in those taking concomitant isoniazid (INH), which inhibits an accessory EFV metabolism pathway via CYP2A6. Patients with a compatible clinical syndrome, in the absence of an alternative cause, should have plasma EFV levels measured and should be switched to a non-EFV-based regimen. Clinical improvement is typically seen within 10–21 days after stopping EFV.

EFV may also cause a drug-induced hepatitis. A subset of these cases appears to occur relatively late, several months or even years after the drug has been initiated.²⁵ It is important that this diagnosis is considered in the differential diagnosis of a subacute hepatitis syndrome. Gynaecomastia can occur with the use of EFV.²⁶ This is not related to lipodystrophy. The onset occurs several months after initiation of ART and it may be bilateral or unilateral. The mechanism appears to be related to oestrogen receptor activation in breast tissue by EFV.²⁷ It is important to exclude other common causes of gynaecomastia, such as other medications (including spironolactone, calcium channel blockers and metoclopramide). A serum testosterone test is useful in excluding hypogonadism as a cause. If serum testosterone is low, then other appropriate investigations should be done to identify the cause and manage accordingly; if serum testosterone is normal, then EFV should be substituted, bearing in mind the general principles of single-drug substitutions (patients who are virologically suppressed should be switched to DTG or RPV). Resolution of gynaecomastia is generally slow, taking months, and may be incomplete in a small percentage.²⁸ It is therefore important to manage the expectations of the patient in this regard.

Rilpivirine

Another option in first-line ART is rilpivirine (RPV) – a second-generation NNRTI. RPV is inexpensive, but not currently available in FDC in the region. An important drawback is that it should not be started in

a patient with a VL > 100 000 copies/mL, as it is inferior to EFV in such patients.²⁹ RPV has a lower incidence of neuropsychiatric side-effects and rashes than EFV.³⁰ There are several important drug-drug interactions with RPV. Among other considerations, RPV cannot be co-administered with RIF or proton-pump inhibitors (PPIs). Histamine type 2 (H2) receptor antagonists need to be administered 12 hours before or 4 hours after taking RPV. RPV should be taken with food to increase absorption.



Common pitfall: Prescribing RPV without first ascertaining the baseline VL. RPV is less efficacious than comparator drugs when the VL > 100 000 copies/mL.

Nevirapine

We no longer recommend nevirapine (NVP) use for new patients starting ART due to the severe toxicity that may be associated with its use. In patients currently tolerating NVP, there is no reason to switch treatment due to toxicity concerns, as toxicity characteristically occurs in the first 3 months of NVP treatment and not later. However, switching for the purpose of simplification to a once-daily regimen should be considered, provided there is virological suppression.

Etravirine

Etravirine (ETR) is a second-generation NNRTI that has been studied in treatment-experienced patients rather than in ART-naïve patients. As is seen with RPV, ETR's activity is not affected by the first-generation NNRTI's signature K103N resistance mutation.

Hypersensitivity with non-nucleoside reverse transcriptase inhibitors

Rash is common with NNRTIs in the first 6 weeks of therapy; notably more severely and frequently with NVP. If the rash is accompanied by systemic features (e.g. fever, elevated alanine transaminase (ALT) or hepatitis), mucosal involvement or blistering, then the NNRTI should be discontinued immediately and re-challenge must not be performed, as these are features of life-threatening reactions. If the rash is mild and occurs without these features, then the NNRTI can be continued and the rash can be treated symptomatically with antihistamines and possibly topical steroids. Systemic steroids should not be used.

If there was a severe reaction to EFV or NVP, then we do not recommend switching to RPV or ETR – rather use DTG or a PI.



Common pitfall: Immediately discontinuing NNRTIs in the case of a mild rash without systemic features. Such rashes often resolve if treatment is continued, although close monitoring is required.

Dosage and common ADRs of NNRTIs available in southern Africa are described in [Table 5](#).


TABLE 5: Dosage and common adverse drug reactions of non-nucleoside reverse transcriptase inhibitors available in southern Africa.

Drug	Recommended dosage	Common or severe ADR [†]
EFV	<ul style="list-style-type: none"> • 600 mg at night (400 mg at night if < 40 kg) • 400 mg dose can also be used in patients > 40 kg 	CNS symptoms (vivid dreams, problems with concentration, dizziness, confusion, mood disturbance, psychosis, late-onset encephalopathy), rash, hepatitis , gynaecomastia
NVP	<ul style="list-style-type: none"> • 200 mg daily for 14 days then 200 mg 12-hourly 	Rash, hepatitis
RPV	<ul style="list-style-type: none"> • 25 mg daily with food 	Rash, hepatitis , CNS symptoms (all uncommon)
ETR [‡]	<ul style="list-style-type: none"> • 200 mg 12-hourly 	Rash, hepatitis (both uncommon)

ADR, adverse drug reaction; CNS, central nervous system; EFV, efavirenz; ETR, etravirine; NNRTI, non-nucleoside reverse transcriptase inhibitors; NVP, nevirapine; RPV, rilpivirine.

[†], Life-threatening reactions are indicated in **bold**.

[‡], NNRTI combinations to be avoided include: (i) ETR + ATV/r (due to drug interaction), and (ii) ETR + DTG unless a boosted PI is also used in the combination (because of drug interaction).





PROTEASE INHIBITOR CLASS OF ANTIRETROVIRAL DRUGS

Key points

- Three protease inhibitor (PI) combinations are recommended in southern Africa: lopinavir (LPV), atazanavir (ATV) or darunavir (DRV), each given with low-dose ritonavir (RTV; indicated as /r) for pharmacokinetic boosting.
- Ritonavir-boosted lopinavir (LPV/r) is the only PI combination that can be used with RIF-based TB treatment, but the dose of LPV/r must be doubled.
- ATV and DRV offer a better side-effect profile than LPV.
- DRV has the highest barrier to resistance of any drug in this class.

Overview of protease inhibitors

Protease inhibitors (PIs) are a class of agents that inhibit HIV's protease enzyme, which is required to cleave HIV's polyproteins into the final protein products that permit the production of infectious viral particles. Inhibition of this process results in immature, non-infectious virions.

Three PI combinations are recommended for use in southern Africa: lopinavir (LPV), atazanavir (ATV) and darunavir (DRV), each given with low-dose ritonavir (RTV; indicated as /r).

RTV is a PI in its own right, but is used principally as a pharmacokinetic 'booster'. As a potent inhibitor of CYP3A4, its use results in higher drug levels and prolonged half-lives of its companion PI. This allows for lower or less frequent PI dosing, and decreases the chance of viral resistance developing. In rare situations, ATV is used without boosting in first-line therapy. However, this inhibition of CYP3A4, together with several other cytochrome P450 enzymes and P-glycoprotein, results in numerous drug-drug interactions with other medications. See [Module 17](#).



Common pitfall: Not using a drug interaction checker when prescribing PI-based ART with other medications. Clinically relevant drug-drug interactions are common with this class.

All PIs may be associated with cardiac conduction abnormalities (especially PR interval prolongation). This seldom results in clinically significant effects, but caution should be taken when co-prescribing other drugs that cause delayed cardiac conduction, such as macrolides or bedaquiline. All PIs are, to some degree, associated with metabolic side-effects. Elevated triglycerides (TG) and elevated low-density lipoprotein cholesterol (LDL-C) are class effects, although these side-effects are more marked with LPV/r than with other PI combinations.^{31,32}

Dosing and common ADRs of PIs are described in [Table 6](#).

Individual protease inhibitors

Lopinavir

Lopinavir (LPV) is co-formulated with ritonavir (LPV/r, e.g. Aluvia). In general, this twice-daily regimen has greater gastrointestinal (GI) side-effects than other PI combinations, and is associated with a worse metabolic profile. LPV is the only PI that can be used concurrently with RIF-based TB treatment; the LPV/r dose has to be doubled in this instance to 800 mg/200 mg twice daily until 2 weeks after RIF has been stopped (see [Module 18](#)).



Common pitfall: Forgetting to double the dose of LPV/r when starting RIF-based TB treatment.

TABLE 6: Dosage and common adverse drug reactions of protease inhibitor drugs available in southern Africa.

Drug	Recommended dosage	Common or severe ADR
ATV/r [†]	<ul style="list-style-type: none"> • ATV/r 300 mg/100 mg daily • If given with EFV, then ATV/r 400/100 mg daily 	Unconjugated hyperbilirubinaemia (visible jaundice in minority of patients), dyslipidaemia (low potential), renal stones (rare), hepatitis (uncommon)
LPV/r	<ul style="list-style-type: none"> • 400 mg/100 mg 12-hourly or • 800 mg/200 mg daily (only if PI-naïve) 	GI upset, dyslipidaemia, hepatitis
DRV/r	<ul style="list-style-type: none"> • 600 mg/100 mg 12-hourly • 800 mg/100 mg daily (only if no DRV mutations) • Consider 400 mg/100 mg daily (only if no DRV mutations) 	GI upset, rash, dyslipidaemia, hepatitis (uncommon). Contains sulphonamide moiety (use with caution in patients with sulpha allergy)

ADR, adverse drug reaction; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; GI, gastrointestinal; LPV/r, ritonavir-boosted lopinavir; PI, protease inhibitor.

Atazanavir

Atazanavir (ATV) is generally better tolerated than LPV and can be taken once daily. It has important drug interactions with drugs that reduce stomach acidity, such as PPIs. ATV may cause an **unconjugated hyperbilirubinaemia** as a result of inhibition of the hepatic enzyme uridine-5'-diphospho (UDP)-glucuronosyltransferase. Though the hyperbilirubinaemia is harmless and does not reflect a drug-induced liver injury (DILI), a minority of patients will become visibly jaundiced, and this may require switching ART regimens for cosmetic reasons.



Common pitfall: Mistaking the unconjugated hyperbilirubinaemia sometimes seen with ATV use with a DILI. Conversely, it is equally important to note that ARVs can also cause a true DILI; therefore, a full liver function test (LFT) panel should be checked to distinguish between the two possibilities.

Darunavir

Darunavir (DRV) has the highest barrier to resistance of any PI. Mutations selected by ATV or LPV can compromise DRV efficiency. For patients with mutations that confer any degree of resistance to DRV (e.g. I50V, L76V, I84V), the dose should be DRV/r 600 mg/100 mg twice daily. For patients without any DRV mutations, the drug can be taken at a dose of DRV/r 800 mg/100 mg once daily. There is evidence, however, that DRV/r 400 mg/100 mg once daily may be sufficient in this scenario, especially for patients with suppressed VLs at the time of the switch.^{33,34} Compared with twice-daily dosing, once-daily dosing

offers the benefits of reduced pill burden and better side-effect profile. As with ATV, DRV cannot be co-prescribed with RIF-based TB treatment.



Common pitfall: Prescribing ATV or DRV for patients receiving RIF-based TB treatment. LPV/r is the only PI combination that can be co-prescribed safely with RIF, but the dose of LPV/r must be adjusted as above.





INITIATION AND TIMING OF ANTIRETROVIRAL THERAPY

Key points

- All individuals diagnosed with HIV should be initiated on ART.
- Delays to starting ART should be minimised. Several studies have demonstrated that it is safe to initiate ART on the same day as diagnosis or on receipt of CD4⁺ count result, with the chief benefit being improved retention in care.
- Screening for tuberculosis (TB), cryptococcal meningitis (CM) and other opportunistic infections (OIs) prior to ART initiation is important, since these conditions may necessitate delaying ART initiation.

Overview

All patients who are diagnosed with HIV should be initiated on ART as soon as possible. Exceptions include patients presenting with cryptococcal meningitis (CM) or tuberculosis meningitis (TBM) – see below.

Benefits of antiretroviral therapy in reducing morbidity and mortality

With ART-induced viral suppression, the CD4⁺ lymphocyte count usually increases, which is accompanied by a restoration of pathogen-specific immune function. For most patients, this results in a dramatic reduction in the risk of HIV-associated morbidity and mortality. For patients who start ART with preserved CD4⁺ counts, ART is able to prevent the decline in CD4⁺ count observed in untreated patients and thereby prevent clinical complications of HIV infection. The benefits in morbidity and mortality extend to patients with relatively preserved CD4⁺ counts. The START and TEMPRANO ANRS 12136 trials showed significant individual clinical benefit when starting ART immediately in patients with CD4⁺ counts > 500 cells/μL rather than deferring until a certain lower CD4⁺ threshold or clinical indication was met.^{35,36}

Benefits of antiretroviral therapy in reducing transmission

The HPTN 052 trial showed that treating the HIV-positive partner in a serodiscordant relationship with ART was associated with a 93% reduction in transmission risk to the uninfected partner, with the

only linked transmissions occurring from partners without a suppressed VL.³⁷ Further evidence in serodiscordant couples from the PARTNER, PARTNER2 and Opposites Attract trials have confirmed that HIV is essentially not transmittable when the VL is suppressed.³⁸⁻⁴⁰ Community-level evidence has also demonstrated a reduction in HIV incidence as ART rollout is scaled up. Therefore, early ART initiation has significant public health benefits.

Antiretroviral therapy in primary HIV infection

In patients who are diagnosed with HIV during **acute seroconversion**, we advise counselling and initiating ART as soon as possible. Expedited ART initiation is preferable as there is evidence that this may limit the size of the HIV reservoir.⁴¹ Once the patient is established on ART, additional counselling may be required for patients who start ART in this acute stage because there is limited time for extensive pre-ART counselling and there is often considerable psychological distress around this time.

Antiretroviral therapy initiation in ‘elite controllers’

A minority of patients (< 1%) have very effective immune control of HIV infection and can control HIV viraemia at undetectable levels even in the absence of ART; these patients are termed ‘*elite controllers*’.

Although definitive data are lacking for this patient subgroup, we advise initiating ART in elite controllers too, as indirect evidence suggests a potential benefit. Elite controllers still have evidence of chronic immune

activation and inflammation that may drive non-infectious morbidities.⁴² Elite controllers have also been shown to have a higher rate of hospitalisation than patients who are virologically controlled by ART.⁴³ Furthermore, a prospective study of HIV-positive 'controllers', who were able to control viral replication to < 500 copies/mL, showed that HIV therapy led to improvements in markers of immune activation and immune exhaustion, and a slightly improved self-reported quality of life.⁴⁴ This trial included elite controllers.

One important consideration in such patients is that careful attention should be paid to confirming the diagnosis of HIV before starting ART. These patients typically have a positive HIV ELISA test, undetectable HIV VL, CD4⁺ count in the normal range and are clinically well. The possibility of a false-positive HIV ELISA test should be excluded either by qualitative HIV DNA PCR or Western Blot assay. If the patient previously had a detectable HIV VL, then this would also serve as confirmation. Such patients may need to be discussed with a laboratory virologist to assist with confirmation of HIV status.



Common pitfall: Not confirming the HIV status of an 'elite controller'. If such patients have been diagnosed with HIV based on an HIV ELISA or rapid test, then confirmation of their HIV status should be sought by additional testing methods to exclude the possibility of a false-positive result.

Commencing antiretroviral therapy at the first clinic visit

Several studies have demonstrated that it is possible to initiate ART safely on the same day as HIV diagnosis or reporting of the CD4⁺ count result.⁴⁵⁻⁴⁷ These studies have demonstrated less overall loss to follow-up when ART is initiated immediately in selected patients. Now that treatment is recommended irrespective of CD4⁺ count, this same-day strategy should be considered as a means to improve retention in care.

Considerations when deciding to initiate ART on the same day as diagnosis:

- The patient should be motivated to start immediately.
- Same-day initiation is not an adherence support 'short cut'; ongoing support can occur in the days and weeks immediately after initiation.
- Patients starting TDF (who are the majority) should be contactable in the event of a CrCl < 50 mL/min, and advised to return to the clinic immediately.
- A serum/plasma CrAg test should be done in patients with a CD4⁺ count < 200 cells/ μ L; again, the patient should be contactable in the event of a positive result, and must be advised to return to the clinic immediately.
- Symptom screening for TB and CM before treatment initiation remains important, and a positive screen requires further investigation prior to ART initiation.



Medical reasons to delay antiretroviral therapy initiation

Medical reasons to delay ART initiation are outlined in [Table 7](#).

TABLE 7: Medical reasons to delay antiretroviral therapy initiation.

Reason	Action
Diagnosis of CM	Defer ART for 4–6 weeks after start of antifungal treatment.
Diagnosis of TBM or tuberculoma	Defer ART until 4–8 weeks after start of TB treatment.
Diagnosis of TB at non-neurological site	Defer ART up to 2 weeks after start of TB treatment if CD4 ⁺ count ≤ 50 cells/μL and up to 8 weeks if CD4 ⁺ count > 50 cells/μL.
Headache	Investigate for meningitis before starting ART.
TB symptoms (cough, night sweats, fever, recent weight loss)	Investigate for TB before starting ART.
Significantly abnormal LFTs (ALT > 200 U/L or jaundice)	Investigate and address the cause before starting ART, including other drugs causing DILI.

ART, antiretroviral therapy; ALT, alanine transaminase; CM, cryptococcal meningitis; DILI, drug-induced liver injury; LFTs, liver function tests; TB, tuberculosis; TBM, tuberculosis meningitis.

Tuberculosis

Decisions regarding the timing of ART in patients with TB should generally be based on the CD4⁺ count.

- **CD4⁺ count ≤ 50 cells/μL:** ART should be regarded as urgent, with the aim to start therapy 2 weeks following the commencement of TB treatment. A meta-analysis of randomised controlled trials (RCTs) has demonstrated that this approach reduces mortality.⁴⁸ It is advised to commence ART after it is clear that the patient's TB symptoms are improving and that TB therapy is tolerated. The exception to this is in the case of CM or TBM (see below).
- **CD4⁺ count > 50 cells/μL:** ART can be delayed until 8 weeks after starting TB treatment, but no later. However, if the patient has other WHO stage 4 conditions, then ART should be initiated 2 weeks after TB treatment is started. The exception to this is CM or TBM. The longer delay before commencing ART in this group is anticipated to reduce the risk of immune reconstitution inflammatory syndrome (IRIS) (see [Module 26](#)). The aforementioned meta-analysis of RCTs did not show a higher risk of AIDS progression/mortality in this group when ART initiation was delayed until approximately 8 weeks after starting TB treatment, but a reduced risk of TB-IRIS.⁴⁸



Tuberculosis meningitis

Patients with TBM are an exception to the above: starting ART immediately or at 2 months following diagnosis was shown to have similarly high mortality, with more complications in the immediate group.⁴⁹ We recommend starting ART 4–8 weeks after TBM diagnosis.

There are important drug interactions and shared side-effects when ART is co-administered with TB therapy (see [Module 18](#)). When ART is commenced, patients should be warned that TB symptoms or signs may temporarily worsen and new features may occur in the first 3 months as a result of TB-IRIS (see [Module 26](#)).

Cryptococcal disease

For patients with CM, the optimal time to start ART is 4–6 weeks from the time of starting CM treatment.

- The COAT (Cryptococcal Optimal ART Timing) trial demonstrated significantly higher mortality in patients who started ART in hospital 1–2 weeks after CM diagnosis than in those starting 5–6 weeks after diagnosis.⁵⁰

For patients diagnosed with cryptococcal antigenaemia who have CM excluded by lumbar puncture (LP), ART can be commenced immediately.

Patients commenced on ART prior to a positive reflex CrAg result should be referred immediately for LP to exclude CM. In patients with a negative cerebrospinal fluid (CSF) CrAg result (i.e. CM is excluded), ART can be continued and fluconazole pre-emptive therapy should be initiated. It is unclear, however, whether to interrupt ART in patients with a positive CSF CrAg result.

For further details refer to the [2019 Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons](#).

Starting antiretroviral therapy in patients with other opportunistic infections and acute illnesses

In the case of most OIs and acute illnesses (e.g. pneumocystis or bacterial pneumonia), the aim should be to initiate ART within 2 weeks of the patient commencing treatment for that infection.⁵¹ In patients with severe Kaposi's sarcoma and lymphoma, ART counselling should be expedited and ART should be initiated as soon as possible.

In HIV-infected patients admitted to hospital and unable to take oral medications, e.g. patients in the intensive care unit (ICU):

- If the patient is receiving ART, then this should be continued – through nasogastric tube (NGT) if necessary – and only interrupted if the GI tract is not functional (e.g. ileus).
- If the patient is not yet receiving ART, then it should not be commenced if the reason for admission is an acute critical illness or injury. There are several potential problems associated with commencing ART in this setting: lack of adequate counselling, GI dysfunction, malabsorption and possible development of resistance.
- There are no intravenous options for ART. In patients admitted to the ICU for prolonged periods, ART initiation in the unit should be considered after multi-organ failure has resolved. Certain ART preparations should not be administered via NGT. In general, paediatric syrups can be administered via NGT. A pharmacist should always be consulted regarding which ART drugs can be administered via NGT and how to do this.



BASELINE INVESTIGATIONS

Confirming the diagnosis of HIV

Prior to the initiation of lifelong ART, it is recommended that HIV infection is confirmed with two different testing methods, at least one of which should be a laboratory-based test. Acceptable combinations include:

- Rapid test + ELISA
- Rapid test + VL
- ELISA + VL.

Note that a VL may be undetectable in < 1% of patients not receiving ART, i.e. 'elite controllers'.

Baseline investigations

Table 8 summarises baseline investigations relevant to ART.

Symptom screen

We also advise a symptom screen for:

- **Tuberculosis (TB):** patients should be asked about cough, weight loss, fever, night sweats and a possible TB contact. If any of these symptoms are present, then sputum should be sent for Xpert analysis; and if hospitalised or CD4⁺ count < 200 cells/μL, then a urine lipoarabinomannan (LAM) assay should be performed.
- **Cryptococcal meningitis (CM):** patients should be asked about new-onset of headache; sCrAg testing and possibly an LP should be performed if this symptom is present.

If the patient's symptom screen is positive, then ART should be deferred until the results of the Xpert, LAM, sCrAg test or LP (as indicated) are known. Delays in this process should, however, be kept to a minimum.

TABLE 8: Summary of baseline investigations for antiretroviral therapy.

Investigation	Comment
CD4 ⁺ count	If CD4 ⁺ count < 200 cells/μL, then CPT is required and serum/plasma CrAg testing needs to be performed.
Baseline VL	Can also serve as a confirmatory HIV test.
ALT	If raised, then will need workup and may influence ART regimen choice.
Creatinine	Avoid TDF if CrCl < 50 mL/min. Other NRTIs, except ABC, require dose adjustment if CrCl < 50 mL/min.
HBsAg	See Module 20 .
Syphilis serology	-
sCrAg	Only required in patients with a CD4 ⁺ count < 200 cells/μL. If sCrAg-positive, exclude CM by LP. See section on CM management (Module 27) for further details.

ABC, abacavir; ALT, alanine transaminase; ART, antiretroviral therapy; CrAg, cryptococcal antigen; CrCl, creatinine clearance rate; CM, cryptococcal meningitis; CPT, cotrimoxazole preventive therapy; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; LP, lumbar puncture; NRTI, nucleoside reverse transcriptase inhibitor; sCrAg, serum cryptococcal antigen; TDF, tenofovir disoproxil fumarate; VL, viral load.



MODULE 8



VIRAL LOAD

Viral load (VL) monitoring is key to the success of ART. Decisions to change ART made on the basis of virological failure, rather than on clinical or immunological failure alone, have been shown to result in better patient outcomes.⁵² If the VL is undetectable, then the virus cannot mutate and develop resistance. A sustained VL < 50 copies/mL is associated with the most durable benefit. A suppressed VL also prevents transmission of HIV to contacts.

Timing of viral load monitoring in the patient starting antiretroviral therapy




FIGURE 1: Timing of viral load monitoring of the patient starting antiretroviral therapy. For patients with a viral load > 50 copies/mL on two consecutive occasions, refer to the text.

(RPV, rilpivirine; VL, viral load)

We recommend performing a **baseline VL** assessment for the following reasons:

1. The 3-month VL can then be compared with the baseline VL to detect > 2 log₁₀ drop, and if this has not occurred, then it allows for early adherence intervention.
2. It may guide NNRTI selection (RPV should not be used if VL > 100 000 copies/mL).
3. It confirms the diagnosis of HIV (antibody tests may very rarely give a false-positive result).

A **3-month VL** assessment is desirable to detect adherence problems early, before resistance develops.

A subset of patients who start ART with a very high VL may not be fully suppressed at 3 months despite 100% adherence, but such patients would have had a > 2 log₁₀ drop in VL from baseline if adherence is optimal and there is no resistance. Therefore, the 3-month result should be interpreted in relation to the baseline VL. All patients who have a detectable VL at 3 months should receive additional adherence interventions. In general, a patient's VL declines fastest on INSTI-based regimens.

If the 3-month VL is undetectable, then VL monitoring is recommended at 6 months and every 6 months thereafter. In patients who have an undetectable VL for

> 12 months, and who demonstrate reliable adherence and follow-up, it may be acceptable to reduce the frequency of VL monitoring to 12-monthly.

If the VL is > 50 copies/mL at any stage, then this should be an indication for urgent action. The patient should receive counselling and interventions should be implemented to improve adherence. A repeat measurement of VL should then be done in 2–3 months.

Interpreting viral load results

Virological criteria for treatment success

Treatment success is defined as a decline in VL to < 50 copies/mL within 6 months of commencing ART, and sustained thereafter.

Virological criteria for treatment failure

Treatment failure is defined as a confirmed VL > 50 copies/mL on two *consecutive* measurements taken 2–3 months apart.

The decision to alter ART should therefore be based on the results of repeat testing after 2–3 months, following intensive adherence counselling. **Although previous guidelines used a threshold of 1000 copies/mL to define virological failure, there is now good evidence that a VL > 50 copies/mL is robustly associated with subsequent virological failure**, although this has not been established.^{53,54} Sustained viral replication, even at these low levels, can lead to the accumulation of resistance mutations (although this has not yet been definitively established in the case of DTG).

Viral blips

Isolated detectable HIV VLs < 1000 copies/mL, followed by an undetectable VL, are termed 'viral blips' and alone are not a reason to change the ART regimen.

- Viral blips can be caused by immune activation (such as from an acute infection), variability in the laboratory testing thresholds, or intermittent poor adherence. Provided that they are infrequent, and the VL returns to being undetectable at the next measurement, they are not regarded as consequential.

Reasons for a high viral load

A high VL can be attributed to one or more of these three factors:

- inadequate patient adherence (most commonly)

- resistance to the prescribed ART – including both acquired and transmitted drug resistance
- inadequate ART drug levels as a result of altered pharmacokinetics, such as absorption difficulties, or drug-drug interactions.

These explanations are not mutually exclusive. For instance, inadequate patient adherence frequently leads to the development of resistance in patients on a non-DTG-containing regimen.

Transmitted drug resistance is currently increasing in the region.⁵⁵ Such drug resistance is most frequently associated with the NNRTI class, since the signature K103N mutation has little effect on viral fitness and can therefore persist in the population even in the absence of drug pressure. Transmitted drug resistance to other drug classes is unusual; therefore first-line therapy with a DTG-based regimen is unlikely to be affected by this phenomenon.

Interpreting a high viral load result in a patient receiving dolutegravir

DTG has proven to be a remarkably robust drug in INSTI-naïve patients when paired with at least one active NRTI. To date, less than five cases of DTG resistance have been described in this scenario. Thus, while a high VL has traditionally been a marker of possible resistance, this paradigm no longer applies for the most part in patients receiving a DTG-based regimen, provided that:

- i. The patient has not had previous exposure to INSTIs as part of a failing regimen.
- ii. The patient is known to have at least one fully active NRTI as part of their regimen. (Note that patients who contract HIV while on pre-exposure prophylaxis (PrEP) are at risk of not having a fully active NRTI backbone.)
- iii. The patient was not recently exposed to a scenario where a drug-drug interaction would have substantially decreased DTG concentrations (e.g. RIF-based TB therapy without increasing DTG dosing frequency to 12-hourly).

Provided that none of the above are met, a detectable VL should not be assumed to reflect possible resistance. Rather, it can be assumed that the detectable VL, if not fulfilling criteria for a viral blip, merely represents poor adherence, and efforts to address this should be undertaken. **We do not recommend performing resistance testing for patients on a DTG-based regimen within 2 years of commencing the drug, provided the above conditions are met.**



CD4⁺ CELL COUNT

Key points

- All HIV-positive patients should be started on ART irrespective of their CD4⁺ counts.
- CD4⁺ counts should be used only to establish whether CTX prophylaxis and sCrAg testing is required (CD4⁺ count < 200 cells/μL).
- Monitoring ART efficacy is best established using VL, not CD4⁺ count.
- Most patients newly initiating ART with an abnormally low CD4⁺ count will see a rapid initial CD4⁺ count increase (75–100 cells/μL), followed by a more gradual rise thereafter (50–100 cells/μL per year) until a normal CD4⁺ count > 500 cells/μL is achieved.
- If CD4⁺ count does not rise despite viral suppression, the ART regimen does need to be altered. This phenomenon may reflect an ‘immunological discordant response to ART’; although if the patient is unwell, then other secondary causes should be sought.

Role of CD4⁺ count monitoring

A CD4⁺ count < 200 cells/μL indicates the need for CTX prophylaxis, principally to prevent *Pneumocystis jirovecii* pneumonia, although CTX is also active against other opportunistic pathogens, including *Toxoplasma gondii*, *Cystoisospora belli* and *Nocardia* spp. A baseline CD4⁺ count < 200 cells/μL is also an indication to reflexly perform sCrAg testing. If the CD4⁺ count > 200 cells/μL at baseline or it increases above this threshold on ART, then CD4⁺ testing can be stopped, since therapeutic monitoring on ART is best accomplished with VL, not CD4⁺ count or clinical criteria. However, if virological or clinical failure occurs, then the CD4⁺ count should be repeated, as CTX prophylaxis should be commenced if the count drops to < 200 cells/μL on ART.



Common pitfall: Routinely checking CD4⁺ cell count if the previous result was > 200 cells/μL.

This is unnecessary unless virological or clinical failure subsequently occurs.

Timing of CD4⁺ count measurements

CD4⁺ counts should be performed:

- At baseline (to guide decisions about CTX prophylaxis)
- Every 6 months thereafter if the previous CD4⁺ count was < 200 cells/μL.

CD4⁺ count response

In patients who start ART with an abnormally low CD4⁺ count, the CD4⁺ count typically increases rapidly in the first month of ART, by ~75–100 cells/μL, with a more gradual rise thereafter (50–100 cells/μL per year).⁵⁶ Most patients achieve a CD4⁺ count > 500 cells/μL after several years of ART, provided that the VL remains suppressed. However, CD4⁺ count responses are highly variable and may fail to increase despite virological suppression in about 10–20% of patients.^{57,58} Such patients have a delayed or absent CD4⁺ count response to ART despite viral suppression, which is termed an ‘**immunological discordant response to ART**’, previously ‘immune non-responders’. Certain studies suggest that older patients are at higher risk of this response. There is no evidence that such patients benefit from a change in ART regimen; therefore, the same regimen should be continued. CTX prophylaxis should be continued if the CD4⁺ count remains < 200 cells/μL. There is evidence that the prognosis of such patients is worse than in those who have a CD4⁺ response, but better than that of patients experiencing both virological and immunological failure.⁵⁸ If patients with an immunological discordant response to ART are clinically unwell, then TB or lymphoma should be considered as the cause of persistent CD4⁺ lymphopenia. CD4⁺ counts may remain stable in the presence of incomplete viral suppression in patients receiving ART until the VL is high (approximately ≥ 10 000 copies/mL).⁵⁹



Common pitfall: Confusing an 'immunological discordant response to ART' with treatment failure.
There is no role for switching ART if the VL is suppressed.

Figure 2 outlines the suggested approach to patients with low CD4⁺ counts despite a suppressed VL on ART.




FIGURE 2: Suggested approach to patients with low CD4⁺ counts despite a suppressed viral load on antiretroviral therapy.

(ART, antiretroviral therapy; CD4⁺, cluster of differentiation 4; OIs, opportunistic infections; SLE, systemic lupus erythematosus; TB, tuberculosis; VL, viral load)





RESISTANCE AND GENOTYPING

KEY POINTS

- Adherence is the key to preventing drug resistance.
- Resistance testing in patients failing DTG-based ART is unnecessary in the majority of cases, and should only be undertaken if specific criteria are met.
- Resistance testing may not detect archived mutations to particular drugs if the patient is not receiving these drugs at the time of resistance testing.

Overview

As a result of transcription errors and recombination, HIV that is replicating can accumulate mutations that lead to drug resistance. Durable viral suppression by ART is required to limit the chances of developing drug resistance. Intermittent drug adherence, as opposed to a total lack of ART, provides a greater opportunity for resistance to develop, by exposing replicating virus to sub-therapeutic ART drug concentrations.

ARV drug resistance mutations are summarised in [Table 9](#).

Drug	Key mutations selected
3TC or FTC	<ul style="list-style-type: none"> • Selects for M184V, which compromises both 3TC and FTC and slightly impairs the activity of ABC, but increases susceptibility to AZT and TDF.
TDF	<ul style="list-style-type: none"> • Selects for K65R, which compromises TDF and ABC but increases susceptibility to AZT. • Also selects for K70E, which causes low-level resistance to TDF, ABC, and possibly 3TC/FTC.
ABC	<ul style="list-style-type: none"> • Selects for L74V, which compromises ABC. • May also select for K65R, which compromises TDF and ABC but increases susceptibility to AZT. • Selects for Y115F, which decreases its susceptibility.
AZT	<ul style="list-style-type: none"> • Selects for TAMs, which may ultimately compromise all NRTIs.
d4T	<ul style="list-style-type: none"> • Selects for TAMs, which may ultimately compromise all NRTIs.
EFV or NVP	<ul style="list-style-type: none"> • Selects for K103N, which causes high-level resistance to EFV and NVP. • Also selects for Y181C and other NNRTI mutations which cause resistance to EFV, NVP, RPV and ETR.
RPV	<ul style="list-style-type: none"> • Selects for several mutations, including E138K, which compromise its susceptibility.
PIS	<ul style="list-style-type: none"> • Multiple mutations usually required before seeing a decrease in susceptibility, especially for LPV and DRV, and cross-resistance between the PIs is common. • ATV selects for I50L, which causes high-level resistance to ATV but not to the other PIs.
RAL	<ul style="list-style-type: none"> • Selects for Q148H/K/R, Y143C and N155H, which cause resistance to RAL and, in certain combinations, to DTG too.
DTG	<ul style="list-style-type: none"> • Very rarely selects resistance if InSTI-naïve, provided it is coupled to at least one other fully active drug. • In patients with prior RAL exposure, mutations such as Q148H may cause decreased DTG susceptibility when combined with additional mutations.

3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; ETR, etravirine; DTG, dolutegravir; FTC, emtricitabine; InSTI, integrase strand transfer inhibitor; LPV, lopinavir; NVP, nevirapine; PIs, protease inhibitors; RAL, raltegravir; RPV, rilpivirine; TAMs, thymidine analogue mutations; NRTIs, nucleoside reverse transcriptase inhibitors; TDF, tenofovir disoproxil fumarate.

When to perform a resistance test

Baseline resistance test

A baseline resistance test is not generally indicated. We recommend a baseline resistance test to guide first-line regimen choice only in the following situations:

1. Pre-exposure prophylaxis (PrEP) received in the previous 6 months
2. History of sexual exposure to a person with known drug-resistant HIV or known to have failed an ART regimen.

Resistance testing at treatment failure

Resistance testing is generally only possible if the VL > 500 copies/mL. Patients with two or more consecutive VL results of 50–500 copies/mL are, however, still considered to have virological failure (see [Module 8](#)).

Recommendations for resistance testing are summarised in [Table 10](#).

Regimen	DTG-based therapy	NNRTI-based therapy	PI-based therapy
First-line	Recommended if patient has been on regimen for > 2 years	Not routinely recommended	Not routinely recommended (rare scenario)
Second-line	Recommended if patient has been on regimen for > 2 years	Recommended (rare scenario)	Recommended if patient has been on regimen for > 2 years

DTG, dolutegravir; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.



First-line therapy

Non-nucleoside reverse transcriptase inhibitor-based therapy

A resistance test at failure of first-line therapy is not routinely recommended. The EARNEST and SELECT trials showed that without the use of a resistance test to decide which NRTIs to use in second-line therapy, virological outcomes were good and equivalent to a boosted PI + RAL regimen.^{60,61} However, where funds permit, resistance testing will offer some advantages:

- A resistance test that shows no drug resistance may prevent having to switch unnecessarily to second-line therapy.
- A resistance test may permit recycling of some first-line NRTIs (e.g. TDF), if they demonstrate susceptibility. This is particularly useful if one wants to carry through TDF (or ABC) to a second-line DTG-based regimen.
- A resistance test will identify drug resistance that may be important to identify should the patient require third-line ART in future.

Dolutegravir-based therapy

Because resistance to DTG in first-line therapy is extremely uncommon, we do not recommend resistance testing unless the patient has been on a

first-line DTG-based regimen for > 2 years, provided they were not exposed to a scenario where a drug-drug interaction would have substantially decreased DTG concentrations (e.g. RIF-based TB therapy without increasing DTG dosing frequency to 12-hourly).⁶² (Other rare indications for performing a resistance test before 2 years include patients who were infected with HIV while receiving pre-exposure prophylaxis (PrEP) – see [Module 11](#).) **Because of the extreme rarity of first-line DTG-based resistance mutations, we suggest switching from a DTG-based first-line regimen to a second-line regimen only if resistance testing shows DTG resistance.**

Second-line therapy

Non-dolutegravir-containing regimens

- Resistance testing is recommended upon failure of **second-line therapy**. This enables clinicians to individualise a treatment regimen for third-line ART.
- For PI-based regimens, sufficient resistance mutations to cause virological failure typically take at least 2 years to develop; therefore, in most cases, we recommend only performing a resistance test after the patient has been on a PI-based regimen for at least this duration. Exceptions include exposure to sub-therapeutic PI drug levels as a result of drug-drug interactions (e.g. not doubling the dose of LPV/r when using RIF-based TB treatment). Patients on PI-based therapy with a VL of 50–500 copies/mL pose a challenge as resistance testing is generally not possible. Such patients should remain on the same regimen with 2–3-monthly VL testing. If the VL rises > 500 copies/mL, then resistance testing should be performed, whereas if the VL re-suppresses to < 50 copies/mL, then the patient may revert to 6–12-monthly VL testing.

Dolutegravir-based therapy

We do not recommend performing resistance testing for DTG-based second-line therapies within 2 years where at least one active NRTI is present. For instance, if the patient's first-line NRTIs were FTC and TDF, and the patient was switched to 3TC and AZT, then the strain of HIV can be assumed to be fully susceptible to AZT.

Scenarios in which to consider resistance testing when failing on a DTG-containing regimen:

- The patient previously developed resistance to other INSTIs (e.g. RAL).

- The ART regimen may not contain any fully active NRTIs.
- Accidental exposure to sub-therapeutic levels of DTG (e.g. RIF-based therapy was commenced without the DTG being given twice daily).

Guide to interpreting a resistance test

Current commercial tests have been licensed for specimens with a VL of at least 1000 RNA copies/mL. Nevertheless, many in-house assays can detect VLs of 500–1000 RNA copies/mL. In general, most commercial HIV resistance tests detect present mutations in > 10–20% of the HIV subpopulations in the sample.



Common pitfall: Performing a resistance test in patients with a low or undetectable VL.

Commercial assays may not be successful in samples where the VL < 500–1000 copies/mL.

A key concept in interpreting resistance tests is **archived resistance**. After reverse transcription from its RNA template, HIV inserts a DNA copy of itself into the host genome. Some of the cells that HIV infects are extremely long-lived, and essentially provide an 'archive' of HIV variants over time. **Thus, mutations that are known to have been present at one point in time can be assumed to be present for the lifetime of the patient, even if they are not visible on the patient's latest resistance test.**

A second key concept is that of the **wild-type virus**, which is the naturally-occurring HIV strain free of drug-resistance mutations. In most cases, this form of the virus replicates more efficiently than viral strains that have acquired resistance. Therefore, when drug pressure is removed, the wild-type forms of the virus will predominate, even though the resistant strains have been archived and can become predominant again later if the drug pressure subsequently changes in ways favourable to these strains.

- A prominent exception is the signature mutation of EFV and NVP, namely K103N, which imposes no significant fitness cost on the virus. Even after these drugs are stopped, the K103N strains may persist at detectable levels for several years.
- Resistance testing should therefore only be performed when the patient is still taking their ART regimen, or up to a maximum of 4 weeks after discontinuation.

- The absence of any identified resistance mutations implies that non-adherence is the cause of a raised VL.
- This does not exclude the possibility of archived resistance, however, which may only become detectable once the patient is back on ART that suppresses the wild-type strain.
- Any significant drug resistance mutations identified by resistance testing can be assumed to be present for the lifetime of the patient, even if subsequent resistance testing fails to show these mutations (as a result of worsened adherence or an ART switch, for instance).
- Conversely, it is only possible to identify mutations reliably for drugs that the patient was currently

taking when the resistance testing was performed, and for drugs affected by cross-resistance. 'Susceptible' results to drugs for which there is no drug pressure may be unreliable due to archived resistance.



Common pitfall: Performing a resistance test in the absence of drug pressure. If the patient has defaulted therapy for more than a few weeks, then there is little purpose for a resistance test. In this scenario, it is highly likely that replication of wild-type virus will overtake and obscure any resistant strain, rendering them undetectable by commercial resistance testing.

BOX 1: Worked example of resistance testing.

A patient was prescribed 3TC + TDF + EFV. When the patient failed this regimen after 1 year, the regimen was switched to 3TC + AZT + LPV/r. After 2 years, the patient failed this regimen too, therefore resistance testing was performed. The results showed the following:

3TC/FTC:	Resistant
TDF:	Susceptible
ABC:	Low-level resistance
AZT:	Resistant
EFV:	Resistant
LPV/r:	Low-level resistance

Interpretation:

- Since the patient was receiving 3TC + AZT + LPV/r at the time of resistance testing, it is possible to interpret the results reliably for these drugs. All show at least a low level of resistance, thus the patient should be switched promptly to an alternative regimen.
- EFV shows resistance, despite the patient not receiving the drug at the time of testing. This phenomenon is not uncommon with the K103N mutation.
- TDF shows susceptibility. The patient was previously exposed to TDF, however. Although it is possible that none of the patient's HIV strains have evolved TDF resistance, the patient was not receiving the drug at the time of resistance testing. Consequently, the possibility of archived resistance to TDF cannot be excluded.

3TC, lamivudine; ABC, abacavir; AZT, zidovudine; EFV, efavirenz; HIV, human immunodeficiency virus; LPV/r, ritonavir-boosted lopinavir; TDF, tenofovir disoproxil fumarate.





INITIAL ANTIRETROVIRAL THERAPY REGIMENS FOR THE PREVIOUSLY UNTREATED PATIENT

Key points

- In ART-naïve patients, the preferred initial regimen is TDF (300 mg) + 3TC (300 mg) (or FTC 200 mg) + DTG (50 mg) daily – available as a once-daily, one-tablet FDC.
- In patients receiving RIF, DTG dosing needs to be increased to 50 mg twice daily until 2 weeks after stopping RIF.
- DTG has been associated with a small excess risk of neural-tube defects (NTDs) in women taking the drug at conception – women of childbearing potential (WOCP) should be counselled accordingly.

Preferred initial antiretroviral therapy regimen

The preferred initial regimen for previously untreated patients is summarised in [Table 11](#).

TABLE 11: Preferred initial antiretroviral therapy regimen for previously untreated patients.

First drug	Second drug	Third drug
TDF 300 mg daily	3TC 300 mg daily; or FTC 200 mg daily	DTG 50 mg daily

3TC, lamuvidine; DTG, dolutegravir; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.

In patients receiving RIF, the DTG dose needs to be increased to 50 mg twice daily until 2 weeks after stopping RIF. Other drug-drug interactions with DTG are discussed in [Module 3](#) and [Module 17](#).

Reasons for this preferred regimen are:

- This combination is available as a once-daily, one-tablet FDC from several suppliers.
- TDF is preferred over ABC due to: the risk of hypersensitivity reactions with ABC (HLA-B*5701 testing is not widely available in SA); certain studies showing lower VL suppression with ABC when baseline VL > 100 000 copies/mL (although not confirmed in a meta-analysis);⁶ and cost.
- 3TC and FTC are regarded as interchangeable in terms of efficacy and safety.
- DTG is preferred over RAL and RPV because of its higher resistance barrier.⁶³ RAL also requires twice-daily dosing and is not co-formulated in FDC. DTG is preferred over EFV and PI

because superior efficacy and tolerability were demonstrated in clinical trials.^{12,13}

- There is an increasing prevalence of pre-treatment resistance to NNRTIs in South Africa (> 10% in some studies) which may compromise efficacy of EFV-based regimens.⁶⁴

DTG has been associated with a small excess risk of neural-tube defects (NTDs) in women taking the drug at conception (0.3% vs. 0.1% in women on EFV at conception in a large Botswana birth-outcomes surveillance study).¹⁸ This risk is lower than originally reported (see [Module 19](#)). Women of childbearing potential (WOCP) should be counselled about this risk and the benefits of DTG, and allowed to make an informed decision regarding the use of DTG and contraception, in line with World Health Organization (WHO) 2019 recommendations. DTG has also been associated with greater weight gain than EFV.²¹ These issues are discussed in [Module 3](#).

Alternative initial antiretroviral therapy regimens

Alternatives regimens for the previously untreated patient are summarised in [Table 12](#).

Regimen	Notes
TDF + 3TC (or FTC) + EFV	<ul style="list-style-type: none"> • EFV can be used at 600 mg <i>nocte</i> or 400 mg <i>nocte</i>. • EFV 400 mg dose is associated with fewer side-effects and less LTFU.²² • EFV 400 mg dose is not available in FDC combination in South Africa. • There are insufficient data to recommend the EFV 400 mg dose in pregnant patients and patients receiving RIF although small-cohort studies have suggested that adequate concentrations are achieved in these patients.^{65,66}
TDF + 3TC (OR FTC) + RPV	<ul style="list-style-type: none"> • RPV cannot be used in patients receiving RIF. • RPV should not be used in initial therapy when baseline VL > 100 000 copies/mL.
ABC + 3TC + DTG	<ul style="list-style-type: none"> • International guidelines recommend HLA-B*5701 testing before prescribing ABC because a negative result rules out the risk of hypersensitivity reaction. However, this genotype is very rare in people of African descent and is thus probably not indicated. • In patients of non-African descent, HLA-B*5701 testing should be considered if ABC is to be used, though access to this test is limited in South Africa.

3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; EFV, efavirenz; FDC, fixed dose combination; FTC, emtricitabine; LTFU, loss to follow-up; RIF, rifampicin; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; VL, viral load.

Alternative initial antiretroviral therapy regimens in specific clinical situations

There are specific clinical situations in which the preferred combination of TDF + 3TC (or FTC) + DTG cannot be used and the alternatives listed in [Table 13](#) are advised instead.

If both TDF and ABC are contraindicated **and** Hb > 8 g/dL, then AZT can be considered as an alternative NRTI.

Scenario	Alternative regimen
Renal impairment at baseline (CrCl < 50 mL/min)	ABC + 3TC + DTG [†]
Renal impairment develops on TDF	ABC + 3TC + DTG
Patient is intolerant of DTG side-effects	TDF + 3TC (or FTC) + EFV (or RPV)
Pure red cell aplasia develops due to 3TC/FTC	TDF + DTG (can then add AZT when Hb has recovered) (or RPV + DTG, provided that the VL is suppressed)

3TC, lamivudine; ABC, abacavir; AZT, zidovudine; CrCl, creatinine clearance rate; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; Hb, haemoglobin; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; VL, viral load.

†, In such patients, if renal function subsequently improves (CrCl > 50 mL/min), then they can be switched to TDF + 3TC + DTG.

Considerations for two-drug first-line regimen of dolutegravir + lamivudine

This regimen was shown to have an efficacy not inferior to a three-drug regimen in RCTs.⁶⁷ However, these trials did not include patients with a VL > 500 000 copies/mL and there are no follow-up data beyond 3 years for this regimen. Furthermore, virological suppression was lower in patients with a CD4⁺ count ≤ 200 cells/μL. Therefore, we do not routinely recommend this regimen unless neither TDF nor ABC can be used. Importantly, HBV must be excluded before considering this regimen as patients with HBV must receive TDF + 3TC (or FTC) to prevent rapid emergence of 3TC resistance. The regimen should also not be used in patients receiving RIF.



MANAGEMENT OF PATIENTS CURRENTLY RECEIVING FIRST-LINE THERAPY

Key points

- Clinicians can consider switching patients who are virologically suppressed on NNRTI-based first-line therapy from an NNRTI to DTG, while maintaining the same two-drug NRTI backbone.
- In patients who are not virologically suppressed on an NNRTI-based regimen (VL > 50 copies/mL), we do not recommend an immediate switch to DTG, but rather enhanced adherence counselling with repeat VL measurement in 2–3 months. If the VL remains > 50 copies/mL, then these patients should be switched to a second-line DTG regimen which includes switching the NRTI backbone.
- The typical criteria to define virological failure, of two VL measurements greater than a certain threshold despite an adherence intervention, are not appropriate for DTG-based regimens. Rather, in patients started on a first-line DTG regimen, we recommend switching to second-line therapy only if there is demonstrated InSTI resistance.

Patients currently on an efavirenz-, rilpivirine- or nevirapine-based first-line regimen

Such patients should have VL measurements performed 6–12-monthly (see [Module 8](#) and [Module 15](#)). Given that DTG is now readily available, clinicians can consider switching patients who are known to **have virological suppression (VL < 50 copies/mL within the last 6 months)** from EFV (or NVP or RPV) to DTG while maintaining the same two-drug NRTI backbone. If the patient is tolerating the EFV (or RPV or NVP) regimen with no side-effects, then such a switch is optional, as the patient may develop DTG-related side-effects that they were not experiencing on the NNRTI (e.g. insomnia, weight gain). The benefit of such a switch is that a DTG regimen has a more robust resistance profile (DTG boasts a higher barrier to resistance than NNRTIs).¹² An additional benefit of switching from NVP to DTG is that it is switching from a twice-daily to once-daily regimen. In patients experiencing EFV-related side-effects (even mild side-effects), we encourage a change to DTG while maintaining the same NRTIs, provided the VL is < 50 copies/mL within the last 6 months.

Another option in patients who are virologically suppressed (VL < 50 copies/mL) while receiving a regimen of NNRTI + two NRTIs, and who have never experienced virological failure, is a switch to the two-drug combination of DTG + RPV. Data from two clinical trials (SWORD I and II)⁶⁸ show that this regimen maintains virological suppression as a switch strategy

in patients who have not previously experienced virological failure. This should not be done in patients who have chronic hepatitis B as TDF and 3TC (or FTC) should always form part of their treatment.

The recommended protocol for switching from a first-line NNRTI-based regimen to a DTG-based regimen is outlined in [Figure 3](#).

Antiretroviral therapy options in patients failing first-line non-nucleoside reverse transcriptase inhibitor-based therapy

In patients who are **not virologically suppressed** on an NNRTI-based regimen (VL > 50 copies/mL), we do not suggest an immediate switch to DTG with the same two NRTIs. The reason is that it is possible that such patients have developed resistance to the two NRTIs and may then be placed on DTG without a fully effective drug to accompany it. In this scenario, we recommend enhanced adherence counselling and repeating the VL measurement in 2–3 months. If the VL is then < 50 copies/mL, then the patient can be switched to DTG + the same two NRTIs. If the VL remains > 50 copies/mL, then the patient should be switched to a second-line DTG regimen which includes DTG + two NRTIs as follows:

- If the patient was receiving TDF (or ABC) + 3TC (or FTC) first-line therapy, then switch to AZT + 3TC in second-line therapy with DTG.
- If the patient was receiving AZT (or d4T) + 3TC first-line therapy, then the decision regarding second-




FIGURE 3: Switching from a first-line non-nucleoside reverse transcriptase inhibitor-based regimen to a dolutegravir-based regimen.

(DTG, dolutegravir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor, VL, viral load)

line therapy should be based on a resistance test result. If the virus is susceptible to TDF on resistance testing, then the clinician can prescribe TDF + 3TC (or FTC) + DTG (provided that the patient has not potentially previously experienced virological failure on TDF, and the patient did not previously experience TDF nephrotoxicity). If no fully active NRTI is available to accompany DTG, then it is best to switch to PI-based second-line therapy with TDF + 3TC (or FTC). Advice is provided in [Module 13](#) regarding patients who cannot access a resistance test in this scenario.

WOCP should be counselled about the potential risk and benefits of DTG, and allowed to make an informed decision regarding the use of DTG and contraception (see [Module 3](#)).

Patients started on a dolutegravir-based first-line regimen

Such patients should have their VL measured 6–12-monthly (see [Module 8](#) and [Module 15](#)). We have previously used the criteria of two VL measurements

> 1000 copies/mL despite an adherence intervention to define virological failure and the need to switch from first- to second-line ART. This was appropriate for patients on NNRTI-based first-line regimens because of the low barrier to resistance of the NNRTI class. However, considerations are very different with DTG-based first-line regimens. In several clinical trials of DTG in first-line therapy, no DTG resistance has been described despite some patients having virological failure; and in clinical practice very few cases of DTG resistance (< 5 cases worldwide at the time of writing) have been described when the drug has been used as part of a three-drug first-line regimen.⁶³ Therefore, it would be inappropriate to use the same criteria for switching to second-line ART for DTG as it is likely that most patients with two unsuppressed VLs will not have resistance and rather require improved adherence on the same first-line regimen to achieve suppression. For that reason, we only recommend switching from first-line DTG-based ART to second-line if resistance testing demonstrates InSTI resistance.

Until further data are available, in patients with an unsuppressed VL on DTG-based first-line ART, we

recommend enhanced adherence counselling. The tolerance of the regimen should also be addressed – the regimen may need to be switched due to side-effects. InSTI-resistance testing should be considered in these situations:

- DTG monotherapy for a period (DTG resistance has been more frequently described in this situation).⁶³
- Co-administration of a drug that interacts with DTG without necessary dose adjustment (e.g. DTG given at 50 mg daily with RIF or given simultaneously with polyvalent cation-containing agents – [Module 3](#)).
- VL measurements > 50 copies/mL for > 2 years (despite adherence interventions, 100% pharmacy refills and self-reported adherence) and current VL is > 500 copies/mL thereby permitting a resistance test
- The patient was infected while receiving PrEP (because of potential NRTI resistance at the time of infection).
- Sentinel surveillance projects or research studies – with the purpose of detecting emergence of DTG resistance.

If a resistance test is performed, then this should include sequencing of the integrase enzyme. The clinician should only switch from a DTG-based first-line regimen to second-line therapy if resistance is detected, and the drugs used in the second-line regimen should depend on the resistance test result (see [Module 13](#)).

These recommendations are based on accumulated information on the resistance barrier to DTG to date suggesting that DTG resistance is extremely rare when the drug is used in a three-drug first-line regimen. These recommendations may be updated when more data become available regarding incidence and risk factors for DTG resistance with more widespread use in routine clinical practice.

[Figure 4](#) outlines the virological monitoring of patients on DTG-based first-line ART and the recommended response to results.




FIGURE 4: Virological monitoring of patients receiving dolutegravir-based first-line antiretroviral therapy and response to results.

(DTG, dolutegravir; NRTIs, nucleoside reverse transcriptase inhibitors; VL, viral load)



MANAGEMENT OF PATIENTS STARTING OR CURRENTLY RECEIVING SECOND-LINE THERAPY

Key points

- When DTG is used in second-line therapy, there should be at least one fully active accompanying drug until further evidence is available.
- If the patient is failing an NNRTI regimen with 3TC/FTC + either TDF or ABC, then AZT + 3TC + DTG is the recommended second-line regimen.
- If the patient is failing other first-line regimens, then resistance testing is advised to decide on the choice of NRTIs in a DTG-based second-line regimen.
- Boosted PI + two NRTI second-line regimens are effective even if there is resistance to both NRTIs in the regimen.
- We advise DRV/r 800 mg/100 mg once daily as the first choice PI for use in second-line therapy.

Recommendations for patients failing a first-line regimen

Failed first-line regimen of two NRTIs + NNRTI

Table 14 summarises the recommended second-line regimen to start in patients who have failed a first-line regimen consisting of two NRTIs + NNRTI.

TABLE 14: Recommended second-line regimen in patients who have failed a first-line regimen of two NRTIs + NNRTI.

Failing first-line regimen	Advised second-line regimen
TDF + 3TC (or FTC) + NNRTI	AZT + 3TC + DTG [†]
AZT + 3TC + NNRTI	Resistance test – if fully active NRTI is available, then combine this with: 3TC (or FTC) + DTG; or TDF + FTC + DRV/r [‡]
ABC + 3TC + NNRTI	AZT + 3TC + DTG [†]

[†], If patient has chronic hepatitis B, then continue TDF, in addition, in the second-line regimen.

[‡], Provided that the patient: has not potentially previously experienced virological failure on TDF; and has not previously experienced TDF nephrotoxicity.

Based on the results of the DAWNING trial, it is preferable to use a DTG-based regimen rather than a PI/r regimen in second-line therapy.¹⁷ In this trial, a second-line regimen of DTG + two NRTIs was superior in terms of virological suppression and better tolerated than LPV/r + two NRTIs in patients who had failed a first-line regimen of NNRTI + two NRTIs. An important caveat is that all patients enrolled in this trial had a resistance test performed at entry and had to have at least one fully active NRTI to be eligible. **Thus, the current evidence supports a DTG-based regimen in second-line ART only when used with at least one fully active NRTI.** Whether a DTG-based second-line regimen would be equally effective with two NRTIs when there is resistance to both those NRTIs is currently a knowledge gap that is

being addressed by several clinical trials – we do not advise such a strategy until the results of those trials are available.

In patients failing a first-line regimen in which the NRTIs are TDF + 3TC (or FTC), the mutations selected are typically M184V by 3TC (or FTC) and K65R (or K70E) by TDF. None of these mutations compromise AZT; in fact they render the virus hyper-susceptible to it. Therefore, in this scenario, AZT remains fully active, and we can infer from the DAWNING trial results that a second-line regimen of AZT + 3TC + DTG will be optimally effective. The same applies for patients failing an ABC + 3TC + NNRTI regimen: AZT retains susceptibility and can be used with 3TC and DTG in a second-line regimen.

Where patients have failed an AZT (or d4T) + 3TC + NNRTI regimen, this could have resulted in the accumulation of thymidine analogue mutations (TAMs) and M184V. Certain TAMs compromise TDF, meaning that it is unpredictable whether there is a fully active NRTI if a regimen of TDF + 3TC (or FTC) + DTG is used in second-line therapy. We therefore advise resistance testing in such patients. If the resistance test demonstrates a fully active NRTI, then that NRTI can be used with 3TC (or FTC) + DTG in the second-line regimen. If there is no fully active NRTI or a resistance test is not possible in this situation (e.g. public sector), then we recommend a regimen of TDF + 3TC (or FTC) + DRV/r. The reason for

this is that boosted PI + two compromised NRTIs retains activity as a second-line regimen (see below).

WOCP must be counselled about the potential risk and benefits of DTG and be allowed to make an informed decision regarding use of DTG and contraception. If such patients choose not to use DTG in second-line therapy, then DRV/r should be used in its place.

Failed first-line regimen of two NRTIs + dolutegravir

The second-line regimen to commence in patients who have failed a first-line approach of two NRTIs + DTG is provided in [Table 15](#).

TABLE 15: Recommended second-line regimen in patients who have failed a first-line regimen of two NRTIs + dolutegravir.

Failing first-line regimen	Second-line regimen advised
Two NRTIs + DTG	Only switch to second-line if the resistance test shows DTG resistance and the second-line should be two NRTIs (selected based on resistance test) + DRV/r

DTG, dolutegravir; NRTI, nucleoside reverse transcriptase inhibitor; DRV/r, ritonavir-boosted darunavir.

If patients experience virological failure on a first-line DTG-based regimen, then we do not recommend switching to second-line therapy unless a resistance test is performed and demonstrates DTG resistance. This is because DTG is a very robust drug and resistance is very rare when used in triple-drug combination first-line therapy. Therefore, it is far more likely that a VL > 50 copies/mL is attributed to adherence problems rather than resistance. If DTG resistance is demonstrated, then we advise a regimen of two NRTIs + DRV/r, with the two NRTIs selected based on the resistance test results.

Patients currently established on a protease inhibitor-based second-line therapy

Viral load < 50 copies/mL

Clinicians can consider switching of patients currently

on a second-line PI/r regimen, to a DTG regimen, particularly in patients experiencing GI side-effects of PIs. This switch may also simplify the regimen and reduce pill burden. However, before such a switch is made, we advise a careful review of the treatment and resistance (genotype test) history **to ensure that there is at least one fully active NRTI** to accompany DTG in the new regimen. If this cannot be assured, then we advise maintaining the current PI/r regimen – though a switch to an alternative PI/r can be considered to improve tolerance. If continuing a PI is not possible, then a switch to a DTG-based second-line regimen without an assured active NRTI could be considered with close VL monitoring. Refer to [Table 16](#) for our advice when considering switching a patient on a PI/r-based regimen to DTG in second-line therapy where the VL < 50 copies/mL.

TABLE 16: Switching from a boosted protease inhibitor to dolutegravir in second-line antiretroviral therapy when the viral load < 50 copies/mL.[†]

First- and second-line regimen: prior ART exposure	Second-line options
First-line TDF + 3TC (or FTC) + NNRTI and second-line AZT + 3TC + PI/r	<ul style="list-style-type: none"> • Can continue same regimen or switch to AZT + 3TC + DTG.
First-line AZT (or d4T) + 3TC + NNRTI and second-line TDF + FTC + PI/r	<ul style="list-style-type: none"> • Preferably stay on the same regimen. • If resistance testing was performed at first-line failure and showed full susceptibility to TDF, then it is possible to switch to TDF + 3TC (or FTC) + DTG. • If no resistance test was performed, but there is intolerance to all boosted PIs, then consider switching to TDF + 3TC (or FTC) + DTG with close virological monitoring (3-monthly) for the first year.

3TC, lamivudine; AZT, zidovudine; DTG, dolutegravir; FTC, emtricitabine; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; TDF, tenofovir disoproxil fumarate.

[†], **Notes:** See [Box 2](#) and [Box 3](#) for more information. ABC is interchangeable with TDF in this table.

VL > 50 copies/mL

In patients on a second-line regimen containing a boosted PI, if the VL is not suppressed, then we do not advise switching to DTG. We advise enhanced adherence counselling and switching to an alternative boosted PI if there is intolerance. If the VL subsequently re-suppresses to an undetectable VL < 50 copies/mL, then the advice in the section above should be followed. If the VL remains elevated, then the patient may be eligible for a resistance test, with consideration for third-line therapy if they fulfill the criteria outlined in [Module 14](#).

BOX 2: Choice of boosted protease inhibitor in second-line antiretroviral therapy.

If a boosted PI is used in second-line therapy, then this is our recommendation in order of preference:

1. DRV/r 800 mg/100 mg daily
2. ATV/r 300 mg/100 mg daily
3. LPV/r 400 mg/100 mg twice daily.

The first choice PI is DRV/r 800 mg/100 mg daily. The once-daily rather than twice-daily dosing can be used in patients who are PI-naïve. Once-daily dosing may facilitate adherence and be better tolerated.⁶⁹

DRV is better tolerated than LPV/r. It has a similar risk of GI intolerance and lipid abnormalities when compared with ATV/r, but does not cause hyperbilirubinaemia as seen with ATV. DRV/r also has a high genetic barrier to resistance.

DRV/r 400 mg/100 mg daily has also been evaluated in switch studies for patients who are suppressed on a PI/r and who have not previously failed a PI. This lower dose of DRV/r retained virological suppression in the vast majority of patients in two trials^{33,34} and in a similar proportion to those who continued LPV/r in one of these trials.³³ Clinicians could consider switching second-line patients who are suppressed on a PI/r to this dose, particularly if cost is an issue.

DRV/r cannot be co-prescribed with RIF and the alternatives to this in second-line therapy are DTG 50 mg twice daily (see above regarding one fully active NRTI), double-dose LPV/r or switching RIF to rifabutin (RFB) (see [Module 18](#)).

Based on clinical trials demonstrating superior tolerability, if DRV/r cannot be used, then we suggest that ATV/r 300 mg/100 mg daily is preferred over LPV/r.^{70,71} The benefits of ATV/r over LPV/r include improved tolerance in terms of GI side-effects, a more favourable lipid profile, and once-daily administration. Drawbacks of ATV/r are: it cannot be used with RIF-based TB treatment; and there are important drug interactions with drugs that reduce stomach acidity such as PPIs. An alternative PI/r rather than ATV/r should be used in the following situations:

- Patients who do not tolerate ATV/r (e.g. cosmetically unacceptable jaundice)
- Patients receiving RIF-based TB treatment: the alternatives to this in second-line therapy are DTG 50 mg twice daily (see above regarding one fully active NRTI), double-dose LPV/r or switching RIF to rifabutin (see [Module 18](#)).

LPV is the third choice PI/r. It is co-formulated with RTV in a heat-stable tablet (Aluvia). LPV/r is an option with RIF when double-dosed. **DRV/r and ATV/r can never be co-administered with RIF-based TB treatment.**

ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; GI, gastrointestinal; LPV/r, ritonavir-boosted lopinavir; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor; PPI, proton pump inhibitor; RIF, rifampicin; RTV, ritonavir; TB, tuberculosis.

BOX 3: Boosted protease inhibitor + two NRTIs is an option in second-line even if there is resistance to both NRTIs.

Because boosted PIs are robust drugs (i.e. resistance develops slowly) in PI-naïve patients, it is very likely that virological suppression will be achieved with good adherence, even if the two NRTIs used in second-line therapy are compromised by NRTI resistance mutations. This is supported by findings of the EARNEST (Europe-Africa Research Network for Evaluation of Second-line Therapy)⁶⁰, SELECT ('Second-Line Effective Combination Therapy' in resource-limited settings)⁶¹ and SECOND-LINE72 trials, which showed good virological suppression rates of second-line LPV/r and NRTI regimens, even in patients with significant NRTI resistance. These trials demonstrated that without the use of a resistance test to decide which NRTIs to use in second-line therapy with PI/r, virological outcomes were good and similar to a boosted PI + RAL regimen. In addition, those patients with more extensive NRTI resistance at first-line failure were more likely to achieve virological suppression in second-line therapy.⁷³

LPV/r, ritonavir-boosted lopinavir; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RAL, raltegravir.



THIRD-LINE ANTIRETROVIRAL THERAPY

Key points

- For patients with a detectable VL on second-line therapy for < 2 years, intensified adherence counselling and support are required rather than a switch to a third-line therapy.
- For a patient on a second-line regimen for > 2 years with two or three VL measurements > 50 copies/mL within a 6-month period **despite adherence interventions that have been assessed to be satisfactory** (see text), then a resistance test should be performed. (**Note:** A resistance test can only be performed if the VL > 500 copies/mL.)
- The choice of the third-line regimen should be made in conjunction with an HIV expert.

Management of patients with a detectable viral load on second-line therapy and initiation of third-line therapy

As outlined above, **there should be documented PI or DTG resistance before switching to a third-line regimen**. Resistance tests should be interpreted by an expert in conjunction with a full ART history. In many patients failing second-line regimens, there are no PI (or DTG) mutations. In these patients, improved adherence is required rather than switching to a third-line regimen. If side-effects interfere with adherence, then consideration should be given to switching to a more tolerable regimen, provided that this regimen is predicted to be effective based on the treatment history (see [Module 13](#)).

[Figure 5](#) outlines the indications for performing resistance testing in second-line ART regimens.

In a patient who has been on a second-line regimen for > 2 years, if there are two or three VL measurements > 50 copies/mL in a 6-month period despite adherence interventions, and adherence is assessed to be satisfactory (e.g. 100% pharmacy claims over 6 months), then a resistance test should be performed (resistance test can only be done if VL > 500 copies/mL). If a patient who has been on second-line therapy for < 2 years is found to have a detectable VL, then a resistance test should not be performed; rather, the same regimen should be continued and adherence counselling and support intensified. The regimen may be switched if there are significant side-effects. It is unlikely that significant resistance to the PI or DTG will

have developed within 2 years. Exceptions include: a patient who in error was not prescribed LPV/r double dosing with concurrent RIF use, and subsequently demonstrates a detectable VL; and a patient who has been taking an incorrectly low dose of medication. Such patients should be eligible for resistance testing even if they have been on second-line therapy for < 2 years.

Adherence counselling before third-line therapy

Specific adherence counselling should be provided for patients preparing to start third-line ART, with a clear discussion that this regimen is likely to be their last option for the foreseeable future.

Third-line regimen choice after failing a protease inhibitor-based second-line regimen

A third-line regimen including a combination of DRV/r and other drugs decided upon based on resistance testing, results in virological suppression in the majority of patients, provided that adherence is optimal.⁷⁴⁻⁷⁷

For most patients who require third-line therapy (experience virological failure on a second-line LPV/r or ATV/r regimen with a low-, intermediate- or high-level resistance to the PI, i.e. Stanford score > 14), **we recommend the third-line regimen** outlined in [Table 17](#). However, the final decision will be based on treatment history and resistance test results for the individual patient.




FIGURE 5: Indications for performing resistance (genotype) testing in second-line antiretroviral therapy.

(ART, antiretroviral therapy; DTG, dolutegravir; LPV/r, ritonavir-boosted lopinavir; PI, protease inhibitor, VL, viral load)

TABLE 17: Third-line regimen recommended for the majority of patients failing protease inhibitor-based second-line therapy.

Second-line regimen failing	Third-line regimen advised
PI-based therapy	TDF 300 mg daily, 3TC 300 mg daily, DTG 50 mg daily (given as TLD) plus DRV/r 600 mg/100 mg twice daily

3TC, lamivudine; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate; TLD, tenofovir disoproxil fumarate + lamivudine + dolutegravir fixed-dose combination (TDF + 3TC + DTG FDC).

Exceptions

There are exceptions:

- In patients with **renal impairment**, replace TDF + FTC with ABC + 3TC, or AZT + 3TC. The choice between ABC and AZT will depend on Hb (**anaemia: do not use AZT if Hb < 8 g/dL**) and resistance testing.
- If the AZT Stanford score is lower than the TDF score, then use AZT + 3TC rather than TDF + FTC.
- Patients with a DRV score of 0 on Stanford score (and no DRV mutations, see [Module 5](#)) can take DRV/r 800 mg/100 mg once daily.

- Patients with prior virological failure on RAL and/or with a DTG score > 0 on integrase resistance testing **should receive DTG 50 mg twice daily**.
- In patients with extensive resistance (e.g. DRV score > 29 and NRTI score > 29), consider adding RPV or ETR (provided the score for these drugs is < 30) or maraviroc (MVC) (provided the virus is CCR5-tropic on the tropism test).

Additional points and explanatory notes

- We generally advise the continuation of NRTIs in the third-line regimen, even if there is documented NRTI resistance.

- 3TC (or FTC) resistance with the M184V mutation impairs viral replication. Another NRTI (generally TDF, but based on resistance testing) should be added. This is not essential if there are more than two other active drugs in the regimen.⁷⁸
- Because most patients are not receiving an NNRTI at the time of failing second-line therapy when a genotype resistance test is typically performed, prior NNRTI mutations related to first-line NNRTI failure may be archived at this time. Therefore, it is difficult to be certain from a (this) genotype performed at second-line ART failure, whether ETR/RPV are still active; however, data from South Africa suggest that the majority of patients who have failed NVP or EFV still have viral susceptibility to ETR/RPV.⁷⁹
- In the SAILING trial, in treatment-experienced patients, a DTG regimen proved superior to RAL and fewer patients in the DTG arm developed treatment-emergent InSTI resistance. **Consequently, we no longer recommend use of RAL in third-line therapy unless DTG is not tolerated or otherwise contraindicated or unavailable.** We also recommend switching patients currently using RAL in third-line therapy to DTG, due to its higher barrier to resistance.¹⁴ If such patients have a suppressed VL, then they can be switched to standard dose DTG (50 mg daily); however, if they are not virologically suppressed, then we suggest a resistance test with a request for integrase sequencing, before switching. If there are InSTI mutations present that are associated with reduced susceptibility to DTG, then the DTG dose should be 50 mg twice daily.
- WOCB should be counselled about the potential risk and benefits of DTG and allowed to make an informed decision regarding the use of DTG and contraception.
- MVC (a CCR5 blocker) is a consideration in third-line therapy; however, it is currently extremely costly and can only be used after a tropism

test demonstrates that the patient's circulating virus has sole tropism for the CCR5 co-receptor. We advise only considering this when there is intermediate- or high-level resistance to all PIs, all NNRTIs and all NRTIs, and DTG does not demonstrate full susceptibility.

- If viral suppression is not achieved on third-line therapy, then there is still benefit in continuing failing ART, because of the residual partial activity and 'crippling' effect of such ART. 'Crippling' describes the fact that mutant viruses often have less replicative capacity. Provided that the VL can be maintained at < 10 000 copies/mL, the CD4⁺ count will usually be maintained or even increase.⁵⁹

Third-line regimen choice after failing a dolutegravir-based second-line regimen

The choice of regimen will be guided by resistance test results and should include DRV/r with two NRTIs (generally 3TC or FTC with the NRTI with the lowest Stanford score). In patients failing a second-line DTG regimen who have not failed a PI/r previously, it can be assumed that DRV/r is fully active and can be used at 800 mg/100 mg daily. Based on the results of the EARNEST, SELECT and SECOND LINE trials, it can be concluded that a DRV/r regimen with two NRTIs will be an active regimen even if there is documented resistance to the two NRTIs.^{60,61,72} However, decisions regarding third-line therapy do need to be individualised in consultation with an expert, taking into account treatment history (which drugs and classes the patient previously failed) and previous and current resistance test results.

RAL may still be active in patients with DTG resistance – it depends on the specific resistance mutations in the integrase gene – but it is usually not necessary to include it in the regimen. ETR and RPV are other drugs that can be considered depending on resistance test results and treatment history.



LABORATORY MONITORING OF THE EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY

Key points

- ART efficacy is monitored with VL and CD4⁺ count – discussed in **Module 8** and **Module 9**.
- The key efficacy endpoint in ART is sustained virological suppression with a VL < 50 copies/mL.
- CD4⁺ count monitoring can be stopped when CD4⁺ count > 200 cells/μL and the VL is suppressed.
- Creatinine monitoring is advised in patients on TDF, and full blood count (FBC) in patients on AZT.
- In most patients taking PIs, only one lipid measurement is advised (at 3 months).

In patients on TDF who are admitted to hospital, it is important to assess creatinine even if it does not fall within these monitoring guidelines. This is because intercurrent illnesses with dehydration or sepsis may be associated with deterioration in renal function, in which TDF may act as a co-factor.

Table 18 lists the laboratory investigations and their frequency advised for monitoring of ART safety.

TABLE 18: Standard laboratory monitoring of patients after commencement of antiretroviral therapy.

Test [†]	When		Comments
	Baseline	Ongoing	
VL	Yes	At 3 months, 6 months and then 6-monthly	• If VL is undetectable for > 12 months, then can reduce to 12-monthly.
CD4 ⁺ count	Yes	6-monthly; At virological/ clinical failure	• Can be stopped if CD4 ⁺ count > 200 cells/μL and virologically suppressed.
FBC and differential count	Yes	Monthly for the first 3 months, then at 6 months for patients on AZT-containing regimens	• This test is only required for patients commencing AZT-containing regimens
ALT	Yes	At initiation	• If baseline ALT is normal, then routine monitoring of ALT is not required.
CrCl	Yes	At 3 months, 6 months and then 6-monthly	• Also at 1 and 2 months in high-risk patients. • If symptoms of tubular wasting (e.g. muscle weakness), then check potassium and phosphate levels.
TC and TG	Not routinely	After 3 months on a PI-containing regimen	• If normal at 3 months, then reassess only if other cardiovascular risk factors are present.

ALT, alanine transaminase; AZT, zidovudine; CD4⁺, cluster of differentiation 4; CrCl, creatinine clearance rate; FBC, full blood count; NVP, nevirapine; PI, protease inhibitor; TC, total cholesterol; TG, triglycerides; VL, viral load.

† These tests should also be performed when clinically indicated, based on the discretion of the clinician.



Common pitfall: Monitoring of VL is not performed at least annually. This results in delayed detection of ART failure and intervention, with resultant clinical deterioration and increased risk of transmission.



PATIENTS WHO RETURN AFTER STOPPING ANTIRETROVIRAL THERAPY

Key points

- Many patients return to care after treatment interruption when they experience clinical deterioration – screening for opportunistic infections (OIs) should be performed.
- VL measurement should be performed before re-initiation, and repeated 3–6-monthly.
- Choosing the appropriate regimen in patients who return to therapy depends on their previous regimen, their level of treatment adherence prior to disengaging from care, and their current CD4⁺ and hospitalisation status.

It is common for patients receiving ART to interrupt their treatment for a variety of reasons (e.g. treatment fatigue, denial, life event, depression, new job, relocation). Many patients return to care after an interruption, often precipitated by clinical deterioration. Patients who have clinical symptoms of an OI when returning to care should be investigated and, if appropriate, started on treatment for the infection before restarting ART. In particular, patients should be screened for headache and for TB symptoms when returning to care. Reasons for delaying ART re-initiation are the same as for delaying initiation in ART-naïve patients (see [Module 6](#)). Patients who are asymptomatic when they return to care could be re-initiated on ART the same day with appropriate counselling. A counselling plan should be implemented to ensure retention in care going forward and address reasons for disengagement.

We recommend performing a VL measurement before re-initiating ART, then 3–6-monthly thereafter. The choice of ART regimen to restart will depend on prior treatment history.

Return after stopping a TDF + FTC (or 3TC) + NNRTI regimen

In patients returning to treatment after disengaging from a TDF + FTC (or 3TC) + NNRTI regimen:

- If the patient was treatment-adherent prior to disengaging, with a suppressed VL, and has only disengaged once or twice, then they could either be restarted on the same regimen or restarted on TDF + 3TC (or FTC) + DTG. If a patient restarts an NNRTI-based regimen, then switching to a

second-line regimen should be considered if the VL is not < 1000 copies/mL at 3 months after restarting.

- **If the patient has a history of poor adherence with multiple episodes of disengaging from treatment, then we suggest re-initiating therapy with a second-line regimen of: AZT + 3TC + DTG; or AZT + 3TC + PI/r; or TDF + FTC + PI/r.** We do not recommend TDF + 3TC (or FTC) + DTG in this scenario, as there may be resistance to TDF and 3TC – multiple episodes of treatment interruption, particularly beyond the first year of ART, and poor adherence can result in resistance to all drugs in the first-line regimen.
- **Hospitalisation with an AIDS-defining condition and a CD4⁺ count < 50 cells/μL** represents another scenario in which a patient may be restarted immediately on second-line ART when returning to care after disengaging. Such patients are considered to be at high risk of mortality if restarted on first-line therapy to which their virus may be resistant; and they require an ART regimen that is guaranteed to be effective immediately. This decision should typically be taken by the hospital-level clinician.

Return after stopping a dolutegravir-based regimen

In patients returning to treatment after disengaging from a DTG-based regimen:

- Restart the same regimen. Assess the VL at 6 months and then follow standard guidance in response to the result.

Return after stopping a TDF + FTC (or 3TC) + PI/r regimen

In patients returning to treatment after disengaging from a second-line PI-based regimen:

- Either restart the patient on the same regimen or switch to AZT + 3TC + DTG (if they had failed a first-line TDF + 3TC (or FTC) + EFV regimen).
- Assess the VL at 6 months and follow standard guidance in response to the result.

Return after stopping a third-line regimen

In patients returning to treatment after disengaging from a third-line regimen:

- Restart the same regimen and assess VL at 6 months. Follow standard guidance in response to the result.



Common pitfall: Performing a resistance test after an ART treatment interruption of > 4 weeks.

Such testing is of limited value. Many resistance mutations are overtaken by wild-type virus when ART is stopped and thus the resistance test may not accurately reflect the true resistance pattern.





DRUG-DRUG INTERACTIONS

Key points

- Whenever patients start or switch ARV drugs or start new concomitant medications, it is important to evaluate for potential drug interactions.
- Many drugs and drug classes have clinically significant drug-drug interactions with ARVs.
- There are also important drug interactions between several ARVs.
- It is important to consult a regularly updated database to assess whether drugs can be co-administered and whether dose adjustment is required.
- Herbal medications (e.g. St John's Wort, garlic) may also have interactions with ARVs, but data on herb-drug interactions are very limited.

Mechanisms of drug interactions

There are two main mechanisms of drug-drug interactions:

Pharmacodynamic interactions occur when one drug influences the action of another drug without altering its concentrations. Such interactions may be beneficial, if drug effects are additive or synergistic, or harmful, if drug effects are antagonistic. Additive toxicity is also a pharmacodynamic interaction (e.g. AZT and linezolid both cause myelosuppression and should not be co-administered).

Pharmacokinetic interactions occur when a perpetrator drug alters the concentrations of a victim drug by affecting its absorption, distribution, metabolism or excretion. Inhibition is a direct chemical effect when a drug binds to the active site of drug-metabolising enzyme or drug transporter – typically only one or a few enzymes or transporters are inhibited. Inhibition is maximal when the inhibiting drug reaches steady state and wanes rapidly when the inhibiting drug is stopped. Strong inhibitors (e.g. ritonavir, clarithromycin, itraconazole) can cause marked increases in concentrations of victim drugs, resulting in toxicity. Induction results in transcriptional activation of many genes involved in drug metabolism and transport, which takes about 2 weeks to be maximal and wanes in a similar timeframe. Strong inducers (e.g. RIF, carbamazepine, phenytoin) can cause marked decreases in concentrations of victim

drugs, resulting in reduced efficacy. Pharmacokinetic interactions are occasionally beneficial (e.g. RTV markedly increases the concentrations of other PIs). Data on herb-drug interactions are very limited – both St John's Wort and garlic are known inducers. Clinically significant pharmacokinetic interactions require dose adjustment of the victim drug or, if the interaction is severe, avoiding co-administration with the perpetrator drug.

Overview of drug-drug interactions by antiretroviral class

- **NRTIs** are generally neither victims nor perpetrators of clinically significant pharmacokinetic interactions.
- **PIs:** RTV is a potent inhibitor of the key cytochrome P450 (CYP) enzyme 3A4 and the drug efflux transporter P-glycoprotein; it also induces several other drug-metabolising enzymes and drug transporters. Therefore, RTV-boosted PIs are frequent perpetrators of pharmacokinetic interactions, but can also be victims of such interactions when co-administered with strong inducers – co-administration with strong inhibitors does not add significantly to the inhibition by RTV. ATV/r requires an acid pH in the stomach for absorption – it should be taken 2 hours before or 1 hour after antacids, and administration with PPIs is not advised.

- **NNRTIs** differ by individual drug. EFV is a moderate inducer. RPV can be the victim when co-administered with strong inducers. Although inhibitors increase exposure to RPV, it is seldom necessary to adjust the dose. ETR induces CYP3A4 and also inhibits two CYP enzymes; it can also be the victim when co-administered with strong inducers.
- **InSTIs:** Polyvalent cations (calcium, magnesium, iron, aluminium) bind to InSTIs, reducing their absorption. InSTIs can be taken 2 hours before or 6 hours after polyvalent cations. However, calcium and iron can be co-administered with InSTIs if taken with a meal, but not in the fasted state. InSTIs are victim drugs when co-administered with strong inducers. InSTIs are not perpetrator drugs, except DTG inhibits an efflux transporter important in the

elimination of metformin (metformin dose should not exceed 500 mg 12-hourly).

There are many important pharmacokinetic drug interactions between ARVs and other drugs, as well as between different ARVs. Some of these drug-drug interactions are discussed in other sections of these guidelines (e.g. interactions with RIF in [Module 18](#)). The full list of all potential drug interactions is very long and beyond the scope of these guidelines.

Knowledge of drug interactions is constantly evolving. Clinicians are advised to seek reliable information on drug-drug interactions when using non-standard ART regimens and when drugs are co-administered, using one or more of the resources listed below.

BOX 4: Contacts and resources for seeking reliable information on drug-drug interactions.

- Package inserts of ARVs and concomitant drugs
- [University of Liverpool HIV Drug Interactions Checker](#)
- [Aid for AIDS clinical guidelines](#) contain tables giving advice on drug-drug interactions
- [University of Cape Town Medicines Information Centre](#) (UCT MIC) has a regularly updated table of interactions between ARVs and drugs used in the public sector (essential medicines list)
- UCT MIC HIV & TB Hotline: [0800 212 506](#) or [021 406 6782](#)



Common pitfall: Not checking for interactions between concomitant drugs and current or newly initiated ARVs. Concomitant drugs may need dose adjustment or discontinuation when ART is switched, e.g. switching from a moderate inducer (such as EFV) to a strong inhibitor (such as a PI/r), or from either of these to an InSTI.



Common pitfall: Not considering marked increases in statin concentrations when used concomitantly with PIs. There are major interactions between PIs and many statins resulting in marked increases in statin concentrations. Low-dose atorvastatin (not exceeding 10 mg, which will give equivalent exposure to ~60 mg) can be used with PIs, but simvastatin cannot be used.



Key points

- Rifampicin (RIF) is a potent inducer of certain drug-metabolising enzymes and drug transporters and reduces exposure to drugs in the InSTI, NNRTI and PI classes, necessitating dose adjustments of certain of these drugs.
- LPV/r is the only PI that can be used with RIF, but the LPV/r dose needs to be doubled.
- Rifabutin (RFB) can be used with all PIs, but a RFB dose adjustment is required.
- Several side-effects are shared between ARVs and TB drugs including GI intolerance, hepatotoxicity, drug rashes, myelosuppression and neuropsychiatric side-effects.

Considerations for antiretroviral therapy in the context of tuberculosis

Tuberculosis (TB) is the most frequent co-infection affecting HIV-positive people in southern Africa. Patients may be diagnosed with TB at entry or re-entry into HIV care, or diagnosed with active TB while on ART. Studies in South Africa have suggested that TB incidence remains higher in patients who are virally suppressed on long-term ART compared with HIV-negative people living in the same community, possibly because of persisting defects in anti-mycobacterial immunity. The co-treatment of HIV and TB is complex because of: (1) drug-drug interactions (discussed below); (2) TB-IRIS ([Module 26](#)); and (3) shared side-effects (discussed below). These issues, which have recently been reviewed,⁸⁰ affect decisions regarding the timing of ART in ART-naïve patients with TB ([Module 6](#)).

Certain ART regimens need to be modified for compatibility with rifampicin (RIF). RIF is a critical component of the drug-sensitive TB regimen that substantially reduces the risk of relapse after completing TB treatment.

There are no significant interactions between NRTIs and RIF; however, InSTIs, NNRTIs, PIs and MVC all exhibit drug interactions with RIF. DTG can be used in patients receiving RIF, but a dose adjustment is required ([Table 19](#)).⁸¹ EFV is the preferred NNRTI for use with RIF. NVP was previously recommended as an alternative in patients with contraindications to EFV (e.g. psychosis), but it carries a higher risk of virological failure when used with RIF, and given

the availability of the InSTI class, NVP is no longer recommended. RPV and ETR cannot be used with RIF. The plasma concentrations of all PI/r are reduced to subtherapeutic ranges with RIF. Dose adjustment of LPV/r can overcome this induction ([Table 19](#)), but there is a risk of hepatotoxicity: patients require counselling and ALT should be monitored frequently.^{82,83}

An alternative approach is to replace RIF with rifabutin (RFB) in patients taking a PI/r. However, RFB is not co-formulated with other TB drugs, and the evidence base for RFB in the treatment of TB is much less substantial than that for RIF.⁸⁴ There is also uncertainty regarding the optimal dose of RFB with PI/r; these guidelines recommend 150 mg daily ([Table 20](#)) for efficacy reasons, but careful monitoring for toxicity is required (ALT, neutrophil count and visual symptoms at least monthly).⁸⁵ RFB may be considered in patients who are not tolerating co-treatment with double-dose LPV/r and RIF-based TB treatment (i.e. patients unable to tolerate the increased LPV/r dose due to hepatotoxicity or GI side-effects) or in ART-experienced patients on an ART regimen that is not compatible with RIF (e.g. third-line ART with DRV/r). If RFB is unavailable and adjusted doses of LPV/r are poorly tolerated in patients receiving second-line ART, then DTG (50 mg 12-hourly) may be substituted for the PI. However, it should be noted that good evidence is lacking regarding the robustness of DTG in second-line therapy with both NRTIs compromised, as exists for PI/r ([Module 13](#)). Nevertheless, the short-term use of DTG with two compromised NRTIs over 6 months is preferable to treating TB without RIF, which has a high risk of failure or relapse.

ART and TB medication share many side-effects ([Table 21](#)).

TABLE 19: Antiretroviral drug interactions with rifampicin and recommendations for co-administration.

Class	ART drug	Interaction	Dose of ART drug with RIF
NRTI	All in class	<ul style="list-style-type: none"> No significant pharmacokinetic interactions 	<ul style="list-style-type: none"> No dose adjustment required
NNRTI	EFV	<ul style="list-style-type: none"> Mild reduction in EFV concentrations INH increases EFV concentrations in genetically slow metabolisers (~20% of South Africans), who already have high EFV concentrations – this can result in toxicity 	<ul style="list-style-type: none"> No dose adjustment required (600 mg <i>nocte</i>)
	ETR and RPV	<ul style="list-style-type: none"> Marked reduction in concentrations 	<ul style="list-style-type: none"> Do not prescribe concomitantly with RIF
PI/r	LPV/r	<ul style="list-style-type: none"> LPV plasma concentrations significantly decreased 	<ul style="list-style-type: none"> Double the dose of LPV/r to 800 mg/200 mg 12-hourly There is an increased risk of hepatotoxicity with this strategy The dose adjustment can be made gradually over 1–2 weeks Dose adjustment should be continued for 2 weeks after RIF is stopped
	All other PI/r	<ul style="list-style-type: none"> Marked reduction in PI concentrations 	<ul style="list-style-type: none"> Do not prescribe concomitantly
InSTI	RAL	<ul style="list-style-type: none"> Reduction in concentrations 	<ul style="list-style-type: none"> Dose increase to 800 mg 12-hourly
	DTG	<ul style="list-style-type: none"> Significant reduction in concentrations 	<ul style="list-style-type: none"> Dosing frequency increased to 50 mg 12-hourly
CCR5 blocker	MVC	<ul style="list-style-type: none"> Reduction in concentrations 	<ul style="list-style-type: none"> Increase MVC dose to 600 mg twice daily when co-administered with RIF in the absence of a potent CYP3A4 inhibitor

ART, antiretroviral therapy; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; INH, isoniazid; InSTI, integrase strand transfer inhibitor; LPV, lopinavir; LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; RAL, raltegravir; RIF, rifampicin; RPV, rilpivirine.

TABLE 20: Dosage of antiretroviral drugs and rifabutin when prescribed concomitantly.

ARV drug	ART dosage	RFB dosage
EFV	No change	Increase to 450 mg/day
InSTI class	No change	300 mg/day
ATV or PI/r	No change	Decrease to 150 mg/day (monitor ALT, neutrophil count and visual symptoms at least monthly)
RPV	Do not co-administer or increase RPV to 50 mg daily	300 mg/day (or 150 mg/day with PI/r)
ETR	Preferably avoid, but if used, then standard doses of ETR	300 mg/day (or 150 mg/day with PI/r)

ALT, alanine transaminase; ART, antiretroviral therapy; ARV, antiretroviral; ATV, atazanavir; EFV, efavirenz; ETR, etravirine; InSTI, integrase strand transfer inhibitor; PI/r, ritonavir-boosted protease inhibitor; RFB, rifabutin; RPV, rilpivirine; RTV, ritonavir.

TABLE 21: Shared side-effects of antiretroviral therapy and tuberculosis treatment.

Side-effects	ART	TB treatment
Nausea	AZT, ddI, PIs	Pyrazinamide, ethionamide, p-aminosalicylic acid (PAS)
Hepatitis	EFV, PIs (NRTIs can cause steatohepatitis)	RIF, RFB, INH, pyrazinamide, bedaquiline and many second-line drugs, including quinolones
Renal impairment	TDF	Aminoglycosides, RIF (rare)
Rash	EFV, RAL, DTG	RIF, RFB, INH, pyrazinamide, ethambutol, streptomycin and many second-line drugs, including quinolones
Neuropsychiatric complications	EFV, DTG	Terizidone/cycloserine, quinolones, INH
Prolonged QTc	RPV	Bedaquiline, quinolones, clofazimine, delamanid
Myelosuppression	AZT	RFB and linezolid


ART, antiretroviral therapy; AZT, zidovudine; d4T, stavudine; ddI, didanosine; DTG, dolutegravir; EFV, efavirenz; INH, isoniazid; NRTIs, nucleoside reverse transcriptase inhibitors; PAS, p-aminosalicylic acid; PIs, protease inhibitors; RAL, raltegravir; RFB, rifabutin; RIF, rifampicin; TB, tuberculosis; TDF, tenofovir disoproxil fumarate; QTc, corrected QT interval.



Common pitfall: RIF is co-administered with LPV/r, but the dose of LPV/r is not adjusted. This results in subtherapeutic LPV concentrations and development of PI resistance. RIF should not be co-administered with ATV/r or DRV/r at all.



Common pitfall: Combining linezolid and AZT. These drugs should not be combined because both can cause bone marrow suppression (especially anaemia and neutropenia).





PREGNANCY AND BREASTFEEDING

Note: It is beyond the scope of these guidelines to provide comprehensive guidance for the management of pregnant women. Key recommendations relating to the mother are included, but providers are encouraged to refer to national guidelines. All women should be linked to routine antenatal care when pregnancy is confirmed.

BOX 5: South African national guidelines for the prevention of mother-to-child transmission of HIV.

- [South African National Department of Health 2019 Guideline for the Prevention of Mother to Child Transmission of Communicable Infections.](#)
- [South African National Department of Health 2019 ART Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates.](#)

- The prevention of mother-to-child transmission of HIV (PMTCT) programme includes peri-conception, pregnancy, delivery and breastfeeding, and encompasses the prevention of unplanned pregnancies.
- In low-resource settings, breastfeeding commonly continues for up to 24 months. Breastfeeding transmission is now the most common mode of mother-to-child transmission of HIV in many parts of sub-Saharan Africa; rendering post-natal retention-in-care vital to successful PMTCT intervention.
- Virological suppression on ART is essential for maternal health, and to prevent HIV transmission to the infant. An elevated VL > 50 copies/mL in a pregnant or breastfeeding woman requires urgent action.
- In well-functioning PMTCT programmes, a significant proportion of infections in infants result from undetected seroconversion during pregnancy and breastfeeding. Repeated HIV testing throughout these periods is essential for women initially testing HIV-negative.
- Interventions that support HIV-risk reduction in women include: male partner HIV testing and linkage to ART for 'treatment as prevention', encouraging consistent condom use throughout pregnancy and breastfeeding, and providing pre-exposure prophylaxis (PrEP) to women at substantial risk of HIV infection.
- Maternal health is central to healthy infants, and is an essential focus of PMTCT services: advanced HIV results in life-threatening OIs, leading to miscarriage, stillbirth, premature delivery and maternal death.

Mother-to-child transmission of HIV

Overall, the risk of mother-to-child transmission of HIV is ~40% in the absence of any intervention. Timing of such transmission is as follows: *in utero*: 5%; during delivery: 15–20%; up to 24 months of breastfeeding: 20%.

The time of highest risk coincides with delivery, which spans a matter of hours; the risk during 24 months of breastfeeding is slightly higher, but over a significantly greater timespan. Breastfeeding should not be stopped because of a new diagnosis of HIV, or an elevated VL in women already on ART. Instead, initiation of ART and management of raised VL (together with infant prophylaxis) are interventions to 'make breastfeeding safer'.



Antiretroviral therapy for women of childbearing potential and during pregnancy and breastfeeding

All HIV-positive pregnant and breastfeeding women should be initiated on lifelong ART, ideally the same day that pregnancy is confirmed. Standard first-, second- and third-line regimens should be used in pregnancy ([Modules 11–14](#)). Regarding DTG use in pregnancy, it is important to note that the absolute risk of neural-tube defects is low (< 0.5%) and this risk may be outweighed by the additional benefits of DTG over alternative therapies. We currently recommend that WOCP who wish to become pregnant or who have no reliable access to effective contraception should be counselled adequately about the potential risks and benefits of DTG- vs. EFV-based ART, and should be offered the choice of first-line regimens.

Other points regarding ART in pregnancy:

- EFV 600 mg is a safe and effective regimen for use by WOCP including during the time from conception to the end of the first trimester. There are insufficient data to recommend routine use of EFV 400 mg in pregnant women.
- These guidelines no longer recommend initiating NVP in any patients. Maternal deaths in pregnant women have been associated with NVP due to liver and skin hypersensitivity reactions.
- NRTIs: contraindications and adverse effects are as for general use. Note that commonly used CrCl calculations are not validated for pregnant women, therefore avoid TDF if sCr \geq 85 μ mol/L.

- Dose adjustment of ART during pregnancy is only indicated for women taking both TDF and ATV/r during the second/third trimester; the dose should be increased from ATV/r 300 mg/100 mg to 400 mg/100 mg.
- Women taking LPV/r 800 mg/200 mg daily should be advised to adjust this to 400 mg/100 mg 12-hourly (twice daily) during pregnancy due to altered pharmacokinetics. These women should also be informed about the association between LPV/r and premature labour and delivery.
- Particular importance should be placed on the drug-drug interactions between DTG and divalent cation-containing medication in pregnancy, since pregnant women frequently receive iron supplements and/or magnesium-/aluminium-containing antacids.

Patients returning to care in pregnancy after defaulting a first-line regimen or those exposed to previous PMTCT regimens should generally be put directly on a DTG-based regimen, rather than retrying an NNRTI-regimen (see also [Module 16](#)). As per current PMTCT guidelines, women not already on ART at the time of labour or delivery should commence TLD immediately and also receive an additional stat dose of NVP 200 mg. Women who are newly diagnosed with HIV during the breastfeeding period may continue breastfeeding as per maternal preference, provided that maternal ART and infant prophylaxis are initiated and adherence support is given.

TABLE 22: Timing of viral load monitoring during pregnancy, delivery and breastfeeding.

Period	ART initiation in pregnancy	Already on ART at diagnosis of pregnancy	Previously taken ART, not currently on treatment (ART interruption, ART for PMTCT)	Newly diagnosed HIV infection during delivery or breastfeeding
Antenatal	VL at baseline and after 3 months of ART: if > 28 weeks' gestation, then repeat VL at delivery	VL at first ANC visit	VL at initiation of DTG-based regimen; repeat VL 3 months later – change in VL determines management	-
Delivery	All women need VL measurement at delivery; review result at day 3–6 postnatal visit			-
Postnatal, up to the end of breastfeeding	VL measure at 6 months postpartum; repeat VL 6-monthly during breastfeeding			VL after 3 months of ART, then 6-monthly during breastfeeding

ANC, antenatal care; ART, antiretroviral therapy; DTG, dolutegravir; PMTCT, prevention of mother-to-child transmission; VL, viral load.

Other key recommendations:

- All pregnant women should be screened at every visit for sexually transmitted infections (STIs) and treated as needed.
- All pregnant and breastfeeding women should be screened for TB at every visit. If the TB screen is negative, then consider TB-preventive therapy during pregnancy only in women with a CD4⁺ count < 350 cells/μL (see [Module 27](#)).



Common pitfall: Not performing VL monitoring at the appropriate time. See [Table 22](#) for the appropriate monitoring intervals.



Common pitfall: An elevated VL is not acted upon urgently. VL results should be fast-tracked, and women failing their current regimen must be identified early and, if necessary, a regimen switch made without delay.





LIVER DISEASE

Antiretroviral drug dose adjustment in liver impairment

Key points

- There is no single blood test for accurate quantification of liver impairment.
- Child-Pugh class C may require dose adjustment for some ARV drugs.
- The combination of TDF + 3TC (or FTC) + DTG (or RAL) is regarded as least hepatotoxic.

Table 23 outlines dose adjustments for the relevant ARV drugs in patients with Child-Pugh class C liver impairment.

TABLE 23: Prescribing antiretroviral therapy in liver impairment.

Class	Drug	Prescribing notes
NRTI	TDF	• No dose adjustment necessary
	3TC	• No dose adjustment necessary
	FTC	• No dose adjustment necessary
	AZT	• Decrease dose by 50% or double dosage interval in significant liver disease
	ABC	• Reduce adult dose to 200 mg twice daily in significant liver disease • Contraindicated in severe liver disease
InSTI	DTG	• No data on recommendation for those with severe liver disease (Child-Pugh class C)
	RAL	• No dose adjustment necessary
PI	DRV	• Use with caution or avoid in significant liver disease
	ATV	• Avoid in severe liver disease
	LPV/r	• LPV is highly metabolised in the liver and concentrations may be increased in patients with hepatic impairment • Therapeutic drug monitoring should be done if available
NNRTI	EFV	• Not recommended in severe liver disease
	ETR	• Use with caution in severe liver disease
	RPV	• Use with caution in severe liver disease (Child-Pugh class C) – dose recommendation not established
CCR5 blocker	MVC	• Concentrations likely to be increased with liver impairment

3TC, lamivudine; ABC, abacavir; ATV, atazanavir; ARVs, antiretrovirals; AZT, zidovudine; CCR5, C-C chemokine receptor type 5; DTG, dolutegravir; DRV, darunavir; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; InSTI, integrase strand transfer inhibitor; LPV, lopinavir; LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; RAL, raltegravir; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate.

Hepatitis B virus/HIV co-infection

Key points

- All HIV-infected individuals should be screened for active hepatitis B virus (HBV) – hepatitis B surface antigen (HBsAg) screening is an appropriate test.
- The HBV VL correlates with disease progression and is used to monitor anti-HBV therapy.
- All children and adults eligible for HBV vaccination should be vaccinated.
- ART drugs with anti-HBV activity are TDF + 3TC (or FTC).
- For all HIV-infected HBsAg-positive patients, the ART regimen should include TDF + 3TC (or FTC).

- Using 3TC without TDF to treat HBV/HIV co-infection leads to HBV resistance in 80–90% of patients after 5 years of treatment.
- Interruption of TDF and/or 3TC (or FTC) has been associated with flares of life-threatening hepatitis in patients with HBV in case reports.
- Adjust dosing frequency of TDF in patients with HBV infection and renal dysfunction; if renal function is severe or deteriorates with TDF, then 3TC monotherapy or other drugs with anti-HBV activity should be considered.

HBV is a common co-infection with HIV in southern Africa, with significant implications for progression to cirrhosis, as well as for treatment options. Access to vaccination, laboratory resources and treatment options is limited to some extent in southern African countries, and the recommendations below should each be considered in the light of the local context.

HBV/HIV co-infection is associated with:

- an increased risk of chronic liver disease
- a higher HBV VL
- diminished responses to HBV vaccine
- an increased risk of drug-induced hepatotoxicity
- a flare of hepatitis within 3 months of commencing ART (due to HBV-related IRIS, which is difficult to differentiate from drug hepatotoxicity).

Drugs directed against HBV that have no/minimal anti-HIV activity (e.g. entecavir and telbivudine) are largely unavailable or extremely expensive in our region. Instead, it is usually necessary to use ART drugs that also have anti-HBV activity: TDF + 3TC (or FTC). As with

HIV, these drugs suppress HBV, but do not eradicate it. Effective treatment prevents or slows progression to cirrhosis. For all HIV-infected hepatitis B surface antigen (HBsAg)-positive patients, the ART regimen should include TDF + 3TC (or FTC). Using 3TC without including TDF leads to the development of HBV resistance in 80–90% of patients after 5 years of treatment. If a patient meets the criteria for switching to a second-line ART regimen (to treat HIV), then this combination – TDF + 3TC (or FTC) – should be continued to suppress HBV infection, as interruption of TDF and/or 3TC (or FTC) has been associated with flares of life-threatening hepatitis in case reports. The second-line ART regimen should be shaped around these two drugs.

In patients with HBV and renal dysfunction, the use of TDF may be considered with dosing frequency adjustment based on CrCl ([Table 24](#)) and more frequent creatinine monitoring. If renal dysfunction is severe or renal function deteriorates with TDF, then 3TC monotherapy or other drugs with anti-HBV activity should be considered.

TABLE 24: Suggested tenofovir disoproxil fumarate dose adjustment in patients with hepatitis B and renal dysfunction.

eGFR (mL/min/1.73 m ²)	Suggested dose of TDF
≥ 50	Usual dose
30–49	300 mg every 48 hours
10–29	300 mg every 72–96 hours
< 10	Avoid (consider 3TC monotherapy, or other drugs with anti-HBV activity)
Haemodialysis	300 mg every week (dose after dialysis on dialysis days)

3TC, lamivudine; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; TDF, tenofovir disoproxil fumarate.



Common pitfall: Not continuing with TDF + 3TC (or FTC) combination when switching to second-line ART. The second-line ART regimen should be shaped around these two drugs.



Common pitfall: Using 3TC without including TDF in the treatment of HIV/HBV co-infected patients.



Key points

- Renal function is estimated by the modified Cockcroft-Gault or modification of diet in renal disease (MDRD) formulae.
- For haemodialysis, the ART prescribed should be taken after dialysis.

In HIV-positive patients on chronic haemodialysis, there are a number of important ART considerations. The NRTI class is eliminated through the kidneys, thus most NRTIs require dose adjustment as per [Table 25](#).⁸⁶⁻⁸⁸ For suggested TDF dosing in patients with chronic hepatitis B, see [Module 20](#).

TABLE 25: Antiretroviral drug dose adjustments in renal failure.^{† 86-88}

Drug	CrCl ^{§,¶}		Haemodialysis (dosage after dialysis)	Peritoneal dialysis
	10–50 mL/min	< 10 mL/min		
TDF	Avoid	Avoid	300 mg once weekly	Unknown
ABC	Unchanged	Unchanged	Unchanged	Unchanged
3TC	150 mg daily	50 mg daily [‡]	50 mg first dose, thereafter 25 mg daily [‡]	50 mg first dose, thereafter 25 mg daily [‡]
AZT	Unchanged	300 mg daily	300 mg daily	300 mg daily
NNRTIs	Unchanged	Unchanged	Unchanged	Unchanged
PIs	Unchanged	Unchanged	Unchanged	Unchanged
InSTIs	Unchanged	Unchanged	Unchanged	Unchanged

3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; AZT, zidovudine; CrCl, creatinine clearance; d4T, stavudine; ddI, didanosine; eGFR, estimated glomerular filtration rate; InSTIs, integrase strand transfer inhibitors; MDRD, modification of diet in renal disease; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; sCr, serum creatinine; TDF, tenofovir disoproxil fumarate.

†, This table was developed using: Bartlett et al., Gilbert et al., and the HIV Medicine Association of the Infectious Diseases Society of America *Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV*.⁸⁶⁻⁸⁸

‡, Some experts recommend that the lowest available tablet dose of 150 mg 3TC daily be used in patients with advanced renal disease (CrCl < 10 mL/min) and patients on dialysis so as to avoid having to use the liquid formulation of 3TC, and because of the favourable safety profile and lack of data to suggest 3TC dose-related toxicity. This is particularly relevant if the 3TC liquid formulation is unavailable or not tolerated.

§, The modified Cockcroft-Gault equation: $CrCl = (140 - \text{age} \times \text{ideal weight}) \div sCr$. For women, multiply the total by 0.85.

¶, Many laboratories report the eGFR calculated using a variation of the MDRD formula. This result can be used (in place of the calculated CrCl) to make decisions regarding the use of TDF and for modification of the dose of other NRTIs based on this table.

Antiretroviral drug choice and dosing in patients on chronic haemodialysis

Key points

- Patients with HIV may develop end-stage renal failure owing to HIV-associated nephropathy or an HIV-unrelated cause, necessitating chronic haemodialysis.
- TDF can be used in patients on chronic haemodialysis, but with once-weekly dosing which can be difficult for patients to remember.
- AZT is generally avoided because of anaemia associated with renal failure.
- InSTIs and NNRTI drugs do not require dose adjustment.
- ATV concentrations are reduced in patients on haemodialysis to a greater degree than LPV concentrations.

- LPV/r requires twice-daily dosing in patients on haemodialysis.
- ART drugs taken once daily, or the evening doses of drugs taken twice daily, should be given after the haemodialysis session on dialysis days, to prevent the drug from being dialysed out.
- Patients on chronic haemodialysis should be reviewed by a clinician experienced in ART management at least 6-monthly, to monitor treatment efficacy and side-effects and to adjust the regimen when needed.

We recommend the following first-line option for patients on chronic haemodialysis: ABC (600 mg daily) + 3TC (50 mg first dose and thereafter 25 mg daily) + DTG (50 mg daily). On the days when haemodialysis is performed, the drugs should be given after the haemodialysis session.



Common pitfall: Not giving daily doses or the evening doses of a twice-daily regimen after the haemodialysis session on dialysis days, to prevent the drug from being dialysed out.

Antiretroviral therapy in patients with acute kidney injury



Key points

- In patients with acute kidney injury (AKI), NRTI dose adjustments should be implemented based on estimated CrCl calculation.
- TDF should be interrupted even if it is not thought to be the cause of the AKI.
- Re-challenge with TDF may be considered in patients 1 month post resolution of AKI if TDF was not the cause and renal function returns to normal
- In patients with AKI who are not yet receiving ART, initiation is preferably deferred until AKI has resolved; but avoid significant delays.
- Once renal function is improving (creatinine is on a downward trend), standard NRTI doses should be re-introduced to avoid under-dosing.

In patients with acute kidney injury (AKI), NRTI dose adjustments should be implemented based on estimated CrCl calculation (see [Table 25](#)). TDF should be interrupted even if it is not thought to be the cause of the AKI. Care should be taken to identify other drugs which may affect renal function, such as aminoglycoside antibiotics, nonsteroidal anti-inflammatory drugs, co-trimoxazole and iodinated radiocontrast; these drugs should be avoided where possible, including temporary discontinuation.

Once there is clear evidence that renal function is improving (i.e. creatinine is on a downward trend), standard NRTI doses should be reintroduced to avoid under-dosing. In patients with AKI who are not yet receiving ART, initiation is preferably deferred until AKI has resolved. However, ART should not be delayed longer than 2 weeks for this reason. If renal function does not show any improvement after treating an acute event (e.g. sepsis) and this persists beyond 3 months, then the patient should be assessed for

chronic kidney disease and referred to a physician who can evaluate and investigate further.



Common pitfall: Not performing NRTI dose adjustment in patients with AKI.





Key points

- DTG may cause insomnia, headache and neuropsychiatric side-effects.
- AZT and RAL frequently cause headaches when started but this usually resolves.
- The majority of patients who experience neuropsychiatric features of EFV do so within the first 2–6 weeks, and thereafter the drug is better tolerated. Late neurological syndromes are described however (see [Module 4](#)).
- Most neuropsychiatric effects relating to ART occur in the first few weeks of therapy.
- Depression and other mental illnesses are often undiagnosed or undertreated in HIV-infected individuals and may undermine adherence.
- Consider avoiding EFV- and RPV- based regimens in patients with psychiatric illness – these drugs can exacerbate psychiatric symptoms and may be associated with suicidality.

Mental health, especially mood and behaviour disorder, is associated with non-adherence to ART, leading to disability and poorer HIV treatment outcomes. There is a higher prevalence of depression in HIV-positive individuals, with a reported range of 20–40% vs. 10% in the general population.⁸⁹

AZT and RAL frequently cause headaches when started, but this usually resolves. EFV frequently causes neuropsychiatric effects in the first few weeks of therapy, typically presenting with insomnia, vivid dreams and dizziness. Both dysphoria and euphoria may occur. Fortunately, these features subside in the majority of patients within the first 4–6 weeks.


Psychosis may occasionally occur. DTG may cause insomnia, headache and neuropsychiatric side-effects. RAL has been associated with similar central nervous system side-effects.



Common pitfall: Not warning patients starting ART about potential neuropsychiatric symptoms. Patients must be informed about potential side-effects.



Common pitfall: Unnecessary delays in initiating ART in patients with psychiatric illness.





Key points

- There are several drug interactions between antimalarial agents and ART drugs.
- EFV has a significant drug interaction with artemether-lumefantrine (Coartem) such that artemether (and its active metabolite) and lumefantrine concentrations are lowered, which can lead to failure of antimalarial therapy. Consider extending the course of artemether-lumefantrine to 6 days if administered concurrently with EFV.
- No artemether-lumefantrine dose adjustment is recommended for patients taking PIs or InSTIs.
- PIs and NNRTIs exhibit several interactions with atovaquone-proguanil (Malanil) such that atovaquone concentrations are reduced – atovaquone-proguanil (Malanil) is best avoided in patients receiving these drugs.
- No significant drug interactions are predicted between InSTIs (DTG) and antimalarial drugs.
- Quinine is best avoided in patients on PIs or NNRTIs.



There are several drug interactions between antimalarials and ART drugs (outlined in [Table 26](#)). While artemether-lumefantrine (Coartem) can be administered safely with NVP, EFV significantly lowers the concentrations of artemether (and its active metabolite) and lumefantrine, which is likely to increase the risk of failure of antimalarial therapy. There is no clear guideline on how to overcome this interaction, but some experts recommend repeating the 3-day course of artemether-lumefantrine (i.e. treat for 6 days). Boosted PIs dramatically increase the plasma concentrations of lumefantrine, but a

dose reduction is not recommended, as the toxicity threshold of lumefantrine seems to be high. Close monitoring for toxicity is recommended when co-administering artemether-lumefantrine with ART.

Quinine concentrations are significantly decreased by LPV/r, probably owing to induction of metabolism by RTV. It is likely that quinine concentrations will also be reduced by EFV and NVP; therefore, quinine should be avoided in patients receiving PIs or NNRTIs. Patients with severe malaria should receive artesunate, if available, and those with milder malaria should be treated with artemether-lumefantrine.

Among drugs used for chemoprophylaxis, there are no clinically significant pharmacokinetic interactions between ARVs and mefloquine or doxycycline. However, mefloquine and EFV both cause frequent neuropsychiatric side-effects; therefore, doxycycline is the preferred chemoprophylactic agent for patients receiving EFV.

There are several interactions with atovaquone-proguanil (Malanil). Atovaquone concentrations are reduced by PIs and EFV, and also likely by NVP. Proguanil concentrations are also reduced by PIs and EFV. Use of atovaquone-proguanil is therefore best avoided in patients receiving PIs or NNRTIs.

No significant drug interactions are predicted between InSTIs and antimalarial drugs.

TABLE 26: Important drug-drug interactions between antimalarial agents and antiretroviral drugs.

Drug	Antimalarial agent	Direction of interaction	Recommendation
InSTI	Coartem (artemether-lumefantrine)	No interaction	Safe to use
	Atovaquone-proguanil	No interaction	Safe to use
EFV	Coartem	↓ artemether and lumefantrine concentrations	Use but might need to repeat the 3-day course of Coartem
	Atovaquone-proguanil	↓ atovaquone and proguanil concentrations	Avoid co-administration
NVP	Coartem	No interaction	Use
	Atovaquone-proguanil	↓ atovaquone concentrations	Avoid co-administration
PI/r	Coartem	↑ lumefantrine concentrations	No dose adjustment necessary
	Atovaquone-proguanil	↓ atovaquone and proguanil concentrations	Avoid co-administration

ART, antiretroviral therapy; EFV, efavirenz; InSTI, integrase strand transfer inhibitor; NVP, nevirapine; PI/r, ritonavir-boosted protease inhibitor.



Common pitfall: Not advising patients receiving ART on chemoprophylaxis for malaria when travelling to malaria-endemic areas.



Common pitfall: Not providing ART recipients with intravenous artesunate or Coartem for malaria treatment despite the potential drug interactions.





ANTIRETROVIRAL DRUG-INDUCED LIVER INJURY

Key points

- All ART classes have been associated with hepatotoxicity and cause injury through an idiosyncratic reaction as the mechanism of injury.
- Alanine transaminase (ALT) elevations $> 5 \times$ the upper limit of normal (ULN) are significant in the absence of symptoms.
- In the presence of symptoms of hepatitis, ALT elevations $> 2.5 \times$ ULN are significant.
- NVP is most frequently associated with drug-induced liver injury (DILI), with most cases occurring in the first few months after initiation. We no longer recommend NVP initiation.
- Patients on EFV may present with a delayed DILI many months after commencing therapy.
- Re-challenge is best avoided and may be considered in select cases in consultation with a specialist.
- If severe hepatitis occurs, or any hepatitis together with a rash, fever or systemic reaction, then re-challenge with NNRTIs, ABC or CTX should not be attempted.

An ALT test should be performed in all patients at ART initiation. Repeat ALT testing is indicated in those who develop symptoms or signs suggestive of hepatitis. All ARV classes have been associated with hepatotoxicity – most commonly NNRTIs. Mild ALT elevations occur commonly and in general are transient. ALT elevations $> 5 \times$ ULN are significant in the absence of symptoms. In the presence of symptoms of hepatitis, ALT elevations $> 2.5 \times$ ULN are also significant. In such patients, potentially hepatotoxic ARVs should be switched to alternative agents. Management guidelines are provided in [Table 27](#).

Re-challenge may be considered, and in selected cases a specialist should be consulted. If severe hepatitis occurs, or any hepatitis with rash, fever, or other systemic manifestation, then the opinion of a specialist should be sought. In this situation re-challenge with NNRTIs, ABC or CTX should not be attempted.

Prolonged use of NRTIs, especially d4T and ddI (both of which are no longer used), may cause fatty liver. Typically, ALT concentration is more significantly elevated than aspartate transaminase (AST), and the concentrations of canalicular enzymes gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) are more elevated than those of the transaminases. Non-tender hepatomegaly may be present. Ultrasound or computed tomography (CT) imaging may show decreased hepatic density. The condition is not benign,

and fibrosis has been reported with long-term ddI use. Patients should be advised to avoid alcohol and should be switched to alternative drugs with lower potential for causing fatty liver.

In patients with severe hepatitis or jaundice, features of hepatic encephalopathy (i.e. features of hepatic failure) must be clinically assessed and the international normalised ratio (INR) and serum glucose checked.

If the concentration of canalicular enzymes is more significantly elevated than that of ALT, or if conjugated bilirubin is elevated, then an ultrasound of the liver should be conducted to exclude biliary obstruction.

Isolated unconjugated hyperbilirubinaemia (drug-induced Gilbert's syndrome) is associated with ATV. In this case, all other LFTs are normal and the patient has no other symptoms of hepatitis. Although this is a benign condition (it does not reflect liver injury, but isolated competitive inhibition of the enzyme in the liver which conjugates bilirubin), it is often cosmetically unacceptable to patients, necessitating a switch from ATV to an alternative drug.

Although EFV has been recognised as an infrequent cause of DILI since it first became available, a novel pattern of DILI associated with the drug has recently been recognised in South Africa.²⁵ Among such patients, many had a particularly severe pattern

of liver injury at liver biopsy (termed ‘submassive necrosis’, and associated with severe jaundice and a raised INR). The overall mortality was 11%. While severe EFV-related DILI is likely to be uncommon, clinicians should be aware of the features observed:

1. The diagnosis of DILI was generally made after a longer duration on EFV (~3–6 months) than what is seen with DILI related to NVP or TB medication
2. The DILI was not associated with features of hypersensitivity (e.g. drug rash) and often the first symptom was jaundice rather than abdominal symptoms
3. Once EFV was stopped, it typically took several months for LFTs to normalise (median resolution > 6 months).

We do not advise routine LFT monitoring in patients on ART, as there is no evidence that this would lead to earlier detection of this DILI or improve outcomes.

Those managing patients on EFV should monitor for symptoms and signs of hepatitis (nausea, vomiting, right-sided abdominal pain, or jaundice). If these occur, then ALT should be assessed, and the patient should be examined for jaundice. The patient should be managed appropriately for DILI if there are hepatitis symptoms with ALT > 120 U/L, or if there is jaundice. EFV should be switched to an alternative drug (e.g. DTG).

Many other drugs can cause hepatotoxicity, notably anti-tuberculous agents (including prophylactic INH) and azoles. CTX is an uncommon cause of hepatitis, often as part of a systemic hypersensitivity reaction.

Recommendations for the management of DILI in patients receiving TB treatment have been published by the Southern African HIV Clinicians Society in 2013: [Management of drug-induced liver injury in HIV-positive patients treated for TB.](#)⁹⁰




TABLE 27: Guidelines for managing hepatotoxicity.

Elevation	ULN [†]		
	< 2.5 × ULN	2.5–5 × ULN	> 5 × ULN
ALT	Repeat at 1–2 weeks	Repeat at 1 week	Discontinue relevant drug(s)
Bilirubin	Repeat at 1 week	Discontinue relevant drug(s)	Discontinue relevant drug(s)

ALT, alanine transaminase; ULN, upper limit of normal.

†, Any elevations with symptoms of hepatitis (nausea, vomiting, right upper quadrant pain) should be regarded as an indication to discontinue the relevant drugs.



Common pitfall: Failing to recognise other drugs apart from ARVs as a cause of hepatotoxicity.



Common pitfall: Performing routine LFT monitoring in patients on ART, in an attempt to detect DILI earlier. There is no evidence to support this approach.




Key points

- PIs can cause hypertriglyceridaemia and elevated low-density lipoprotein cholesterol (LDL-C).
- ATV/r and DRV/r are associated with less significant lipid abnormalities than LPV/r.
- EFV can cause elevated total cholesterol (TC) and mild hypertriglyceridaemia.
- DTG does not significantly affect cholesterol.
- Lipids should be assessed routinely after 3 months on a PI regimen.

PIs can cause hypertriglyceridaemia and elevated LDL-C. ATV/r and once-daily DRV/r (800 mg/100 mg DRV/r) are associated with less severe dyslipidaemia than other boosted PIs; AZT can cause mild hypertriglyceridaemia, and EFV can cause elevated total cholesterol (TC) and mild hypertriglyceridaemia.

We suggest that lipids should be assessed routinely after 3 months on a PI regimen. If normal at this

stage, then reassessment should be performed only in those with cardiovascular risk factors. Diet and lifestyle modification should always be advised. Diet is more effective for controlling hypertriglyceridaemia than hypercholesterolaemia. Other cardiovascular risk factors should be addressed. Clinicians should consider and investigate secondary causes of hypertriglyceridaemia and hypercholesterolaemia (e.g. diabetes, nephrotic syndrome, alcohol abuse and hypothyroidism).



If patients receiving LPV/r develop significant dyslipidaemia, then they should be switched to DRV/r or ATV/r, rather than adding lipid-lowering therapy. However, lipid-lowering therapy is indicated in patients with persistent elevations despite switching to DRV/r or ATV/r. Switching the PI to DTG is another option, because DTG has a more favourable lipid profile than PIs. However, DTG should only be used in a regimen in which at least one other ART drug is known to be fully active. In patients with hyperlipidaemia on EFV, the drug should be switched to DTG or RPV.

Marked hypertriglyceridaemia (> 10 mmol/L) can cause pancreatitis and requires urgent treatment with diet modification (restrict total TG intake to < 30 g/day), fibrates and switching of LPV/r to DRV/r, ATV/r or DTG. (Fibrates can be stopped after 1 month, followed by reassessment within 4–6 weeks.)

Indications for statin therapy in HIV-positive patients should be the same as in HIV-negative patients, using the Framingham heart disease risk score. As a general rule, in young patients with isolated elevated cholesterol but no other cardiovascular risk factors, a threshold of TC > 7.5 mmol/L (or LDL-C > 5.0 mmol/L) should be used

for initiating statin therapy; and the patient should be referred to a lipid clinic for investigation if feasible. In patients with cardiovascular risk factors (e.g. smoking, diabetes, hypertension), decisions should be made using the [Framingham heart disease risk score](#). All patients with established atherosclerotic disease (coronary, cerebral or peripheral) or familial hypercholesterolaemia should be started on statin treatment. In addition, type 2 diabetics should also be started on a statin if they have chronic kidney disease, or if they are aged > 40 years (or have had diabetes for > 10 years) and have one or more additional cardiovascular risk factors.⁹¹

Many statins have interactions with PIs that can lead to potentially toxic statin concentrations, with the exception of pravastatin and fluvastatin. Atorvastatin concentrations are significantly raised by PIs, but low doses (maximum 10 mg daily) can be used with monitoring for symptoms of myalgia. Lovastatin and simvastatin should not be co-administered with PIs, as their concentrations are dramatically increased, and severe rhabdomyolysis has been reported. We also advise against the use of rosuvastatin with PIs due to a complex drug-drug interaction: PIs increase the plasma concentrations of rosuvastatin while reducing their efficacy in the liver.



Common pitfall: Not routinely assessing lipids while the patient is receiving PI-based ART.



Common pitfall: Failure to recognise that many statins have interactions with PIs that lead to toxic statin concentrations.



Common pitfall: Monitoring of LDL-C in patients on a high-dose statin for secondary prevention. Such monitoring is not necessary.



IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME

Key points

- Approximately 10–20% of patients who start ART with advanced immunosuppression experience immune reconstitution inflammatory syndrome (IRIS) in the first few months of treatment.
- Two forms of IRIS have been recognised, namely unmasking and paradoxical IRIS.
- IRIS is most frequently described in association with tuberculosis (TB) and cryptococcal meningitis (CM).
- InSTIs are not associated with an increased risk for TB-IRIS in clinical trials.
- Early ART initiation (defined as 1–4 weeks after anti-tuberculous therapy) doubles the risk of TB-IRIS compared with late ART initiation (defined as 8–12 weeks after anti-tuberculous therapy), but ART should not be delayed for this reason in patients with CD4⁺ count < 50 cells/μL.
- There is no confirmatory diagnostic test for IRIS.
- In most instances, ART is continued in cases of IRIS, unless IRIS is life-threatening (e.g. neurological involvement in TB-IRIS with depressed level of consciousness).
- Corticosteroids have been shown to reduce morbidity and improve symptoms in paradoxical TB-IRIS.

Approximately 10–20% of patients who start ART with advanced immunosuppression experience clinical deterioration during the first few months due to IRIS. Most presentations of IRIS occur within the first 3 months of ART. Two forms are recognised:

- **Unmasking IRIS** occurs in patients who have an unrecognised opportunistic infection (OI) when ART is initiated, and who then present with exaggerated inflammatory features of that infection during early ART due to it being ‘unmasked’ by recovering immunity.
- **Paradoxical IRIS** occurs in patients who are being treated for an OI when they start ART, but who develop an immune-mediated worsening or recurrence of features of that infection after starting ART.

IRIS is most frequently described in association with TB and CM. Skin conditions such as molluscum contagiosum and Kaposi’s sarcoma may also worsen due to IRIS. The diagnosis of IRIS can be difficult, mainly because there is no confirmatory diagnostic test. Diagnosis relies on recognition of the characteristic clinical presentation, ensuring that OIs

are correctly diagnosed, and excluding alternative causes for deterioration, such as drug resistance (e.g. multidrug-resistant TB). Case definitions for TB and cryptococcal IRIS have been published.^{92,93} It is important to ensure that the underlying OI is treated appropriately. ART should be continued, unless the IRIS is life-threatening (e.g. neurological involvement in TB-IRIS with depressed level of consciousness). Corticosteroids have been shown to reduce morbidity and improve symptoms in paradoxical TB-IRIS,⁹⁴ and can be used in mycobacterial and fungal forms of IRIS when other causes for deterioration have been excluded, and particularly when IRIS features are severe.

For paradoxical TB-IRIS, prednisone can be commenced at a dose of 1.5 mg/kg/day and weaned over 4 weeks, but a longer course may be required if symptoms recur on weaning.⁹⁵ Steroids should not be used in patients with Kaposi’s sarcoma.



Common pitfall: Using steroids in patients with Kaposi’s sarcoma.

Prophylactic prednisone

Key points

- Upon starting ART, patients with active TB who are improving on TB therapy and have a CD4⁺ count ≤ 100 cells/ μL , can be initiated on prednisone 40 mg daily for 14 days followed by 20 mg daily for 14 days to prevent paradoxical TB-IRIS.
- The use of prednisone in this context is not associated with excess risk of severe infections, cancers or adverse events.

The use of prophylactic prednisone for the prevention of paradoxical TB-associated IRIS in adults with a CD4⁺ count ≤ 100 cells/ μL has been shown in a randomised trial to be associated with a 30% lower relative incidence of TB-IRIS.⁹⁶ Importantly, this did not come at the expense of any excess risk of severe infections or cancers. The recommended prednisone regimen is 40 mg daily for 14 days, followed by 20 mg daily for 14 days, and the prednisone should be started

concurrently with ART. Certain patient groups should be excluded from receiving prednisone, however, including patients with Kaposi's sarcoma and patients with RIF-resistant TB, or whose TB has not improved prior to starting ART.



Common pitfall: Using prophylactic prednisone in patients who are not improving on TB therapy.





OPPORTUNISTIC INFECTION PROPHYLAXIS

Key points

- The use of appropriate prophylaxis (primary or secondary) is essential in patients initiating ART.
- In general, prophylaxis can be discontinued once the CD4⁺ count has increased to > 200 cells/ μ L, but certain minimal durations of prophylaxis apply for secondary prophylaxis.
- Local and international guidelines should be consulted.

Cotrimoxazole primary prophylaxis

Prophylactic cotrimoxazole (CTX) is indicated for HIV-positive patients with a CD4⁺ count < 200 cells/ μ L, or with WHO stage 3 or 4 conditions (including TB). CTX offers protection against *Pneumocystis jirovecii*, toxoplasmosis, isosporiasis and certain bacterial infections. The recommended dose is 160 mg/800 mg daily. Patients who develop a hypersensitivity reaction to CTX can be given dapsone instead, although this is best avoided if the reaction to CTX was life-threatening. CTX can be discontinued once the patient's CD4⁺ count > 200 cells/ μ L.

CTX is a common cause of cutaneous and systemic hypersensitivity reactions, indistinguishable from hypersensitivity reactions to ART drugs. CTX should be interrupted when treating mild suspected NNRTI cutaneous hypersensitivity rashes, and permanently discontinued if severe hypersensitivity reactions occur. If CTX is prescribed for secondary prophylaxis or used for primary prophylaxis in those with severe immunosuppression, then an alternative should be substituted.



Common pitfall: Prescribing CTX for newly diagnosed HIV-positive patients with a high CD4⁺ count (> 200 cells/ μ L).

Cryptococcal antigen screening and pre-emptive treatment

Key points

- CrAg screening should be done for all adults or adolescents with a CD4⁺ count < 200 cells/ μ L who are initiating or re-initiating ART.
- Reflex laboratory screening is the preferred approach in South Africa.
- Lumbar puncture (LP) is recommended for all patients with a new positive CrAg screening test.

Screening for subclinical cryptococcal disease has been shown to have a benefit in reducing mortality in HIV-infected patients with a CD4⁺ count < 200 cells/ μ L. It is recommended that HIV-seropositive adults or adolescents (\geq 10 years) with a CD4⁺ count < 200 cells/ μ L should be screened for cryptococcal antigenaemia (CrAg) on serum or plasma by reflex laboratory testing (preferred) or clinician-initiated testing. If clinician-initiated testing is performed, then it is recommended that screening should be restricted to adults or adolescents without prior cryptococcal disease who are initiating or re-initiating ART. For patients with a new positive CrAg result and an LP that rules out CM, oral fluconazole alone as induction therapy should be given (adults 1200 mg daily for 2 weeks). In these patients with a negative CSF CrAg result, ART can be started immediately with fluconazole.

Patients diagnosed with CM should be managed as per the latest [Southern African HIV Clinicians' Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update](#).



Common pitfall: Not performing an LP in all patients who are newly diagnosed as CrAg positive.

The absence of any symptoms of meningitis does not exclude CM; approximately one in three patients with asymptomatic antigenaemia have concurrent CM.

Isoniazid preventive therapy

Key points

- Isoniazid preventive therapy (IPT) should be started at ART initiation or added to the treatment regimen of patients already on ART who have not yet received IPT, once active TB has been excluded.
- There is no need to test for latent TB prior to commencing IPT.
- IPT should not be started in pregnancy, except in pregnant women where the CD4⁺ count is < 350 cells/ μ L and who are at high risk of death from TB.
- Before commencing IPT, active TB infection should always be excluded.

Clinical trials conducted in South Africa and Cote d'Ivoire have shown that IPT has an additive effect with ART in preventing incident TB in HIV-infected patients.^{97,98} In the South African trial, there was a 37% reduction in incident TB when patients receiving ART were prescribed IPT (vs. placebo) for 12 months. This benefit applied irrespective of tuberculin skin test (TST) status, and the trial included patients established on ART. All patients receiving ART should be considered for IPT and screened for active TB using a symptom screen⁹⁹ – IPT should be deferred and investigations conducted for active TB if any of the four symptoms (current cough, fever, night sweats or weight loss) are present. In patients receiving IPT, monitoring for neuropathy and hepatitis symptoms

should be performed. Routine ALT monitoring is not indicated, but ALT should be tested if hepatitis symptoms occur.

A recent trial of IPT in pregnant women receiving ART, the TB APPRISE study, showed that IPT resulted in worse pregnancy outcomes.¹⁰⁰ However, this was not confirmed in a larger observational study from the Western Cape, which showed that IPT use was associated with better pregnancy outcomes, and that incident TB was reduced in women on IPT who had CD4 counts <350 cells/ μ L.¹⁰¹ The duration of IPT is now 12 months irrespective of TST status as outlined in [Table 28](#).

TABLE 28: Indications for isoniazid preventive therapy (provided that there are no tuberculosis symptoms nor contraindications to isoniazid).

Patient category	IPT	Duration
Non-pregnant, regardless of CD4 ⁺ count	Indicated	12 months
Pregnant women with CD4 ⁺ count > 350 cells/ μ L	Not indicated	N/A
Pregnant women with CD4 ⁺ count < 350 cells/ μ L (at high risk for TB)	Indicated	12 months

ART, antiretroviral therapy; CD4⁺, cluster of differentiation 4; IPT, isoniazid preventive therapy; N/A, not applicable; TB, tuberculosis.



ADHERENCE

Patient readiness for antiretroviral therapy

Key points

- Each patient commencing ART needs to be prepared for treatment before or during the early ART period.
- Barriers to adherence (e.g. depression, alcohol use, non-disclosure or food security) and any misconceptions about ART must be identified in the preparation for ART or during the early period of ART.

Preparing patients for lifelong ART with good adherence is a critical component of achieving long-term efficacy and preventing treatment resistance. To accommodate counselling, traditionally two or three visits were required, staggered closely together, before ART. However, it is now considered acceptable to do certain of the counselling during early ART rather than delaying initiation (same-day initiation is described in [Module 6](#)).

Prolonged delays in commencing ART should be avoided. ART should be delayed only if concerns about

adherence are severe enough to outweigh the risk of HIV disease progression.

The patient should be provided with details regarding:

- the benefits of ART
- that ART is life-long therapy
- the importance of good adherence
- a list of ART side-effects relevant to the drugs that the patient will use, including what to do and who to contact if serious side-effects occur
- VL monitoring on ART.



The counselling approach should also ensure that the patient has a good understanding of HIV (the virus, the potential clinical complications and transmission), and should cover safer-sex practices and address issues related to reproductive health (i.e. family planning, contraception, condom use and pregnancy). Clinicians should check family-planning choices at follow-up visits and ensure adequate access to safe and effective contraception. It is important to discuss the concept of '*Undetectable = Untransmittable*' with patients and ensure that they have a correct understanding of this concept and that ART will only prevent onward transmission if there is optimal adherence with VL suppression.

Active depression, other mental health issues or substance abuse should be detected actively and treated. A personal treatment plan should be formulated for each patient, specifying drug storage,

strategies for missed doses and how to integrate taking medication into their daily routine. The patient must be made aware of scheduling in terms of clinical follow-up.

Disclosure of HIV status (to a partner and/or other household members) should strongly be encouraged; it is an important determinant of treatment adherence and assists in the provision of patient-directed support. Disclosure also identifies exposed contacts for screening and support. This issue needs to be handled sensitively in situations where disclosure may have harmful consequences, particularly for women. The patient should be encouraged to join a support group and/or identify a treatment 'buddy.' However, neither disclosure nor support group participation are prerequisites for good adherence, and should not be a reason for deferring ART. Clinicians should ensure that they have the contact details of each patient and their treatment buddy.



Common pitfall: Delaying ART because the patient has not completed three clinic visits or not disclosed their HIV status.



Common pitfall: Not outlining the goals of ART with the patient. These are to:

- Provide maximal and durable VL suppression.
- Restore and preserve immune function.
- Reduce HIV-related infectious and non-infectious morbidity.
- Prolong life expectancy and improve quality of life.
- Prevent onward transmission of HIV.
- Minimise adverse effects of the treatment.

Support and counselling

Key points

- Success of ART hinges on how well the tablets are taken; at least 90%, preferably more, of treatment doses need to be taken.
- Support should be provided to ensure high levels of treatment adherence.
- None of the commonly used first- and second-line options have meaningful food restrictions.
- Delayed dosing is rarely a problem; even if out by many hours, most of the drugs have long half-lives, and patients should be encouraged and supported to take their dose once they remember to do so in these instances.
- Disclosure is not a prerequisite for ART.
- Heavy alcohol use may affect adherence and may potentiate ART hepatotoxicity and other hepatic pathology; however, responsible alcohol use is not prohibited in patients established on or starting ART.

Patients should be informed about the benefits of ART and that side-effects are usually minor and transient, or manageable. They should be given a treatment plan, specifying the drugs to be used (with names and details including the appearance of each drug, when and how they are to be taken, and a brief indication of anticipated side-effects and toxicity).

The causes of poor adherence are often complex and linked to social issues. Common causes for poor adherence are outlined in [Table 29](#).

TABLE 29: Possible reasons for poor adherence.

Individual	Provider	Medication
<ul style="list-style-type: none"> • Depression • Alcohol or substance use • Non-disclosure • Inadequate treatment literacy • Adolescence • Following pregnancy • Food security • Work-related issues (shift work) • Social problems (stigma and poor social support networks) 	<ul style="list-style-type: none"> • Stock-outs • Inaccessible clinics (both in place and time) • Poor communication (not patient-centred) 	<ul style="list-style-type: none"> • High pill burden • Frequent dosing (> once per day) • Adverse effects



Common pitfall: Not informing patients of the benefits of ART. This includes not only reduced mortality and morbidity, but also prevention of HIV transmission.



Common pitfall: Not informing patients that side-effects are usually minor and transient, or manageable.



Common pitfall: Not advising patients on how to deal with delayed dosing.



Common pitfall: Not providing patients with a treatment plan specifying the drugs to be used.



Algorithm for initiation of antiretroviral therapy

Confirm HIV diagnosis before starting ART

- Rapid test + ELISA; or
- Rapid test + VL[†]; or
- ELISA + VL[†]

[†], VL may be undetectable in < 1% of patients on ART ('elite controllers')

Baseline tests

- CD4⁺ count: if < 200 cells/μL, then perform sCrAg and start CTX prophylaxis
- VL
- ALT: if significantly abnormal (> 200 U/L or jaundice), then investigate cause before starting ART
- Creatinine: if CrCl < 50 mL/min (or creatinine < 85 μmol/L in pregnant women), then avoid TDF
- HBsAg
- Syphilis serology
- sCrAg: exclude CM by LP if positive

Symptom screen

- TB
 - Cough, fever, weight loss, night sweats, TB contact
 - Send sputum for Xpert analysis, and perform urine LAM test if CD4⁺ count < 200 cells/μL or if the patient is hospitalised
- CM
 - New onset headache
 - Perform sCrAg +/- LP

Symptom screen negative

- Initiate ART

Symptom screen positive

- Defer ART until results of additional tests are known

ALT, alanine transaminase; ART, antiretroviral therapy; CD4⁺, cluster of differentiation 4; CrCl, creatinine clearance rate; CM, cryptococcal meningitis; CTX, cotrimoxazole; ELISA, enzyme-linked immunosorbent assay; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; LAM, lipoarabinomannan; LP, lumbar puncture; PI, protease inhibitor; sCrAg, serum cryptococcal antigen; TB, tuberculosis; TDF, tenofovir disoproxil fumarate; VL, viral load.

Summary of antiretrovirals and adverse effects

Nucleoside/nucleotide reverse transcriptase inhibitors

NRTI	Recommended dose	Common or severe ADR
TDF	• 300 mg daily	• Renal failure, tubular wasting syndrome, reduced bone mineral density, nausea
3TC	• 150 mg 12-hourly or 300 mg daily	• Anaemia (pure red cell aplasia) (rare)
FTC	• 200 mg daily	• Anemia (pure red cell aplasia) (rare), palmar hyperpigmentation
ABC	• 300 mg 12-hourly or 600 mg daily	• Hypersensitivity reaction
AZT	• 300 mg 12-hourly	• Anaemia, neutropenia, GI upset, headache, steatohepatitis (medium potential), lipoatrophy

Non-nucleotide reverse transcriptase inhibitors

NNRTI	Recommended dose	Common or severe ADR
EFV	• 600 mg or 400 mg <i>nocte</i>	• CNS symptoms (vivid dreams, problems with concentration, dizziness, confusion, mood disturbance, psychosis, late onset encephalopathy), rash, hepatitis, gynaecomastia
NVP	• 200 mg daily for 14 days then 200 mg 12-hourly	• Rash, hepatitis
RPV	• 25 mg daily with food	• Rash, hepatitis, CNS symptoms (all uncommon)
ETR	• 200 mg 12-hourly	• Rash, hepatitis (both uncommon)

Protease inhibitors

PI	Recommended dose	Common or severe ADR
ATV/r	• 300 mg/100 mg daily; if given with EFV ATV/r 400 mg/100 mg daily	• Unconjugated hyperbilirubinaemia (visible jaundice in a minority of patients), dyslipidemia (low potential), renal stones (rare) and hepatitis (uncommon)
LPV/r	• 400 mg/100 mg 12-hourly or 800 mg/200 mg daily (only if PI-naïve)	• GI upset, dyslipidemia and hepatitis
DRV/r	• 600 mg/100 mg 12-hourly • 800 mg/100 mg daily (only if no DRV mutations) • Consider 400 mg/100 mg daily (only if no DRV mutations)	• GI upset, rash, dyslipidemia, hepatitis (uncommon). Contains sulphonamide moiety (use with caution in patients with sulpha allergy)


Integrase strand transfer inhibitors

InSTI	Recommended dose	Common or severe ADR
RAL	• 400 mg 12-hourly	• Headache and other CNS side-effects, GI upset, hepatitis and rash (rare), rhabdomyolysis (rare), weight gain
DTG	• 50 mg daily	• Insomnia, headache and other CNS side-effects, GI upset, hepatitis and rash (rare). possibly teratogenic, weight gain

- Package inserts of all ARVs and concomitant drugs
- [University of Liverpool HIV Drug Interactions Checker](#)
- [Aid for AIDS clinical guidelines](#) contain tables giving advice on drug-drug interactions
- [University of Cape Town Medicines Information Centre \(MIC\)](#) has a regularly updated table of interactions between ARTs and drugs used in the public sector (essentials medicines list)
- MIC HIV & TB Hotline: 0800 212 506 or 021 406 6782

3TC, lamivudine; ABC, abacavir; ADR, adverse drug reaction; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; CNS, central nervous system; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; GI, gastrointestinal; InSTI, integrase strand transfer inhibitor; LPV/r, ritonavir-boosted lopinavir; MIC, Medicines Information Centre; NVP, nevirapine; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; RAL, raltegravir; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate.

Viral load monitoring




Treatment success = VL < 50 copies/mL within 6 months of starting ART and sustained thereafter.

Treatment failure = confirmed VL > 50 copies/mL on two consecutive measurements taken 2-3 months apart despite intensive adherence counselling.

Viral blips = isolated detectable VL followed by undetectable VL. These are not a reason to change ART regimen.

ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; RPV, rilpivirine; VL, viral load.


Viral load monitoring on dolutegravir-based first-line regimens



ART, antiretroviral therapy; DTG, dolutegravir; NRTIs, nucleoside/nucleotide reverse transcriptase inhibitors; VL, viral load.

CD4⁺ count monitoring

- Repeat CD4⁺ count every 6 months if previous count < 200 cells/ μ L.
- Any CD4⁺ count < 200 cells/ μ L: start CTX and perform sCrAg test (+/- refer for LP if sCrAg-positive).
- CD4⁺ count > 200 cells/ μ L: does not necessitate repeat testing unless virological or clinical failure occurs.
- After starting ART, a gradual rise in CD4⁺ count is expected. Do not alter the ART regimen if CD4⁺ count does not rise despite viral suppression (immunological discordant response to ART); look for secondary causes if the patient is unwell.



ART, antiretroviral therapy; CD4⁺, cluster of differentiation 4; CTX, cotrimoxazole; LP, lumbar puncture; OIs, opportunistic infections; sCrAg, serum cryptococcal antigen; SLE, systemic lupus erythematosus; TB, tuberculosis; VL, viral load.

Resistance tests

- Resistance testing should not be performed in a patient with a low or undetectable VL. Resistance testing is generally only possible if VL > 500 copies/mL.
- Resistance testing should be performed when a patient is on an ART regimen or up to 4 weeks after discontinuation.

Regimen	DTG-based therapy	NNRTI-based therapy	PI-based therapy
First-line regimen	Recommended if patient on regimen for > 2 years [†]	Not routinely recommended	Not routinely recommended
Second-line regimen	Recommended if patient on regimen for > 2 years [‡]	Recommended	Recommended if patient on regimen for > 2 years [†]

[†], Unless indicated earlier (e.g. accidental exposure to sub-therapeutic drug levels as a result of drug-drug interactions; infected while on PrEP for DTG-based therapies; DTG monotherapy)

[‡], Unless indicated earlier (patient previously developed resistance to other InSTIs; ART regimen may not contain any fully active NRTIs; accidental exposure to sub-therapeutic levels of DTG).

ART, antiretroviral therapy; DTG, dolutegravir; InSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; PrEP, pre-exposure prophylaxis; VL, viral load.

Initiation of antiretroviral therapy in previously untreated patients

Preferred first-line regimen:


TDF (300 mg) + 3TC (300 mg) (or FTC 200 mg) + DTG (50 mg) daily as FDC

Alternative initial ART regimens:

Regimen	Comment
TDF + 3TC (or FTC) + EFV	<ul style="list-style-type: none">• EFV can be used at 600 mg or 400 mg <i>nocte</i> dose (dose associated with fewer side-effects).• Insufficient data for 400 mg dose in pregnant patients and those receiving RIF.
TDF + 3TC (or FTC) + RPV	<ul style="list-style-type: none">• Cannot be used in patients receiving RIF.• RPV should not be used as initial therapy where VL > 100 000 copies/mL.
ABC + 3TC + DTG	<ul style="list-style-type: none">• HLA-B*5701 testing indicated prior to prescribing ABC – consider in non-African descent; rare in African descent.• Use if renal impairment at baseline (TDF contraindicated when CrCl < 50 mL/min) or if renal impairment develops while on TDF.
<ul style="list-style-type: none">• If TDF and ABC are contraindicated and Hb > 8 g/dL, then use AZT + 3TC (or FTC) as the NRTI backbone• If pure red cell aplasia develops because of 3TC/FTC, then give TDF + DTG (add AZT when Hb has recovered) (or RPV + DTG provided the VL is suppressed)	

3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; AZT, zidovudine; CrCl, creatinine clearance rate; DTG, dolutegravir; EFV, efavirenz; FDC, fixed-dose combination; FTC, emtricitabine; Hb, haemoglobin; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; RIF, rifampicin; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; VL, viral load.

Switching patients on non-nucleoside reverse transcriptase inhibitor-based first-line regimens to a dolutegravir-based regimen: Guided by viral load



Benefits and risks of DTG and EFV	
DTG	EFV
<ul style="list-style-type: none"> • High genetic barrier to resistance • Rapid VL suppression 	<ul style="list-style-type: none"> • Low genetic barrier to resistance
<ul style="list-style-type: none"> • Side-effects mild and uncommon • Weight gain • Insomnia 	<ul style="list-style-type: none"> • Neuropsychiatric side-effects
<ul style="list-style-type: none"> • No interaction with hormonal contraceptives • Interaction with RIF,[‡] metformin, some anticonvulsants, polyvalent cations 	<ul style="list-style-type: none"> • Drug interactions with contraceptives and many medicines metabolised by liver • No significant interaction with TB treatment
<ul style="list-style-type: none"> • Increased risk of NTDs during conception[†] 	<ul style="list-style-type: none"> • Safe in pregnancy

[†], Counsel WOCP regarding the risk of NTDs associated with DTG during conception in order to enable informed decision-making: determine pregnancy status; offer contraception for all women who do not wish to conceive.

[‡], Double the dose of DTG (50 mg twice daily) when co-administering RIF.

[§], Add TDF in second-line regimen in patients who are HBsAg-positive to avoid hepatitis flare.

3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; HBsAg, hepatitis B surface antigen; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NTDs, neural-tube defects; PI, protease inhibitor; RIF, rifampicin; TB, tuberculosis; TDF, tenofovir disoproxil fumarate; VL, viral load; WOCP, women of childbearing potential.

Protease inhibitor-based second-line regimens

- Choice of boosted PI in second-line ART:
 - DRV/r (800 mg/100 mg) > ATV/r (300 mg/100 mg) > LPV/r (400 mg/100 mg).
 - DRV/r and ATV/r cannot be given with RIF; instead use double-dose LPV/r, or switch to DTG if possible, or use RFB instead of RIF.

Switching patients on PI-based second-line regimens to a DTG-based regimen: Guided by VL


First- and second-line regimen: Prior ART exposure	Second-line options	VL > 50 copies/mL:
First-line TDF + 3TC (or FTC) + NNRTI and second-line AZT + 3TC + PI/r	<ul style="list-style-type: none"> Can continue the same regimen or switch to AZT + 3TC + DTG 	
First-line AZT (or d4T) + 3TC + NNRTI and second-line TDF + FTC + PI/r	<ul style="list-style-type: none"> Preferably stay on the same regimen If resistance testing was performed at first-line failure and showed full susceptibility to TDF, then it is possible to switch to TDF + 3TC (or FTC) + DTG If no resistance test was performed, but there is intolerance to all boosted PIs, then consider switching to TDF + 3TC (or FTC) + DTG with close virological monitoring (3-monthly) for the first year. 	

- VL > 50 copies/mL:**
 - Switching to a DTG-based regimen is not advised
 - Provide adherence counselling, and consider switching if the VL is suppressed
 - If the VL is still elevated, then a resistance test for third-line regimens may be indicated.

3TC, lamivudine; ART, antiretroviral therapy; ATV/r, ritonavir-boosted atazanvir; AZT, zidovudine; d4T, stavudine; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; FTC, emtricitabine; LPV/r, ritonavir-boosted lopinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor; RIF, rifampicin; RFB, rifabutin; TDF, tenofovir disoproxil fumarate; VL, viral load.

Third-line antiretroviral therapy regimens

- Patient on second-line therapy for < 2 years with detectable VL: adherence counselling rather than a switch to a third-line regimen.
- Patient on second-line therapy for > 2 years with two or three detectable VLs within a 6-month period despite adherence interventions: perform resistance test.
- Choose regimen with HIV expert.



ART, antiretroviral therapy; DTG, dolutegravir; HIV, human immunodeficiency virus; PI, protease inhibitor; VL, viral load.

Monitoring of antiretroviral therapy

Standard laboratory monitoring of patients after commencement of antiretroviral therapy.

Test [†]	When		Comments
	Baseline	Ongoing	
VL	Yes	At 3 months, 6 months and then 6-monthly	<ul style="list-style-type: none"> If VL is undetectable for > 12 months, then can reduce to 12-monthly
CD4 ⁺ count	Yes	6-monthly; At virological/clinical failure	<ul style="list-style-type: none"> Can be stopped if CD4⁺ count > 200 cells/μL and virologically suppressed
FBC and differential count	Yes	Monthly for the first 3 months, then at 6 months for patients on AZT-containing regimens	<ul style="list-style-type: none"> This test is only required for patients commencing AZT-containing regimens
ALT	Yes	At initiation	<ul style="list-style-type: none"> If baseline ALT is normal, then routine monitoring of ALT is not required
CrCl	Yes	At 3 months, 6 months and then 6-monthly	<ul style="list-style-type: none"> Also at 1 and 2 months in high-risk patients If symptoms of tubular wasting (e.g. muscle weakness), then check potassium and phosphate levels
TC and TG	Not routinely	After 3 months on a PI-containing regimen	<ul style="list-style-type: none"> If normal at 3 months, reassess only if other cardiovascular risk factors are present

ALT, alanine transamine; AZT, zidovudine; CD4⁺, cluster of differentiation 4; CrCl, creatinine clearance rate; FBC, full blood count; PI, protease inhibitor; TC, total cholesterol; TG, triglycerides; VL, viral load.

Opportunistic infection prophylaxis

- CTX (160 mg/800 mg):
 - Start if CD4⁺ count < 200 cells/μL or if WHO stage 3 or 4 disease.
 - Discontinue when CD4⁺ count > 200 cells/μL .
- IPT:
 - Start at time of ART initiation, or in patients on ART who have not yet received IPT.
 - Do not start during pregnancy, except in pregnant women where the CD4⁺ count < 350 cells/μL and who are at high risk of death from TB.
 - Active TB must be excluded.
 - Provide for 12 months (no TST needed).
 - Test ALT only if hepatitis symptoms or jaundice develop.

ALT, alanine transamine; CD4⁺, cluster of differentiation 4; CTX, cotrimoxazole; IPT, isoniazid preventive therapy; TB, tuberculosis; TST, tuberculin skin test; WHO, World Health Organization.

REFERENCES

1. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: Collaborative analysis of cohort studies. *PLoS Med*. 2013;10(4):e1001418. <https://doi.org/10.1371/journal.pmed.1001418>
2. Maartens G. 'Covering the tail' after stopping efavirenz-based antiretroviral therapy. *S Afr J HIV Med*. 2020;21(1):a1036. <https://doi.org/10.4102/sajhivmed.v21i1.1036>
3. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. *Hepatology*. 1999;30(5):1302–1306. <https://doi.org/10.1002/hep.510300525>
4. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. *AIDS Res Treat*. 2011;2011:354908. <https://doi.org/10.1155/2011/354908>
5. Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. *South Afr J HIV Med*. 2018;19(1):817. <https://doi.org/10.4102/sajhivmed.v19i1.817>
6. Cruciani M, Mengoli C, Malena M, et al. Virological efficacy of abacavir: Systematic review and meta-analysis. *J Antimicrob Chemother*. 2014; 69(12):3169–3180. <https://doi.org/10.1093/jac/dku279>
7. D. A. D. Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. *Lancet*. 2008; 371(9622):1417–1426. [https://doi.org/10.1016/S0140-6736\(08\)60423-7](https://doi.org/10.1016/S0140-6736(08)60423-7)
8. Ribaud HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-term results from ACTG A5001/ALLRT. *Clin Infect Dis*. 2011;52(7):929–940. <https://doi.org/10.1093/cid/ciq244>
9. Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S, Santoscoy M, Nieto-Cisneros L. Lamivudine-induced pure red cell aplasia. *Am J Hematol*. 2000;65(3):189–191. [https://doi.org/10.1002/1096-8652\(200011\)65:3<189::AID-AJH2>3.0.CO;2-6](https://doi.org/10.1002/1096-8652(200011)65:3<189::AID-AJH2>3.0.CO;2-6)
10. Cohen K, Viljoen C, Njuguna C, Maartens G. Emtricitabine-associated red cell aplasia. *AIDS*. 2019;33(6):1095–1096. <https://doi.org/10.1097/QAD.0000000000002136>
11. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis*. 2013;13(11):927–935. [https://doi.org/10.1016/S1473-3099\(13\)70257-3](https://doi.org/10.1016/S1473-3099(13)70257-3)
12. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med*. 2013;369(19):1807–1818. <https://doi.org/10.1056/NEJMoa1215541>
13. Molina JM, Clotet B, Van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. *Lancet HIV*. 2015;2(4):e127–e136. [https://doi.org/10.1016/S2352-3018\(15\)00027-2](https://doi.org/10.1016/S2352-3018(15)00027-2)
14. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. *Lancet*. 2013;382(9893):700–708. [https://doi.org/10.1016/S0140-6736\(13\)61221-0](https://doi.org/10.1016/S0140-6736(13)61221-0)
15. You J, Wang H, Huang X, et al. Therapy-emergent drug resistance to integrase strand transfer inhibitors in HIV-1 patients: A subgroup meta-analysis of clinical trials. *PLoS One*. 2016;11(8):e0160087. <https://doi.org/10.1371/journal.pone.0160087>
16. Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): Week 48 results from a randomised, open-label, non-inferiority, phase 3b study. *Lancet HIV*. 2017;4(12):e536–e546. <https://doi.org/10.1093/ofid/ofw194.89>
17. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): An open-label, non-inferiority, phase 3b trial. *Lancet Infect Dis*. 2019;19(3):253–264. [https://doi.org/10.1016/S1473-3099\(19\)30036-2](https://doi.org/10.1016/S1473-3099(19)30036-2)
18. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. *N Engl J Med*. 2019;381(9):827–840. <https://doi.org/10.1056/NEJMoa1905230>
19. Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir use at conception – Additional surveillance data from Botswana. *N Engl J Med*. 2019;381(9): 885–887. <https://doi.org/10.1056/NEJMc1908155>

20. Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? *J Virus Erad.* 2019;5(1):41–43.
21. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med.* 2019;381(9):803–815. <https://doi.org/10.1056/NEJMoa1902824>
22. Encore Study Group, Carey D, Puls R, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. *Lancet Infect Dis.* 2015; 15(7):793–802.
23. Variava E, Sigauke FR, Norman J, et al. Brief report: Late Efavirenz-induced ataxia and encephalopathy: A case series. *J Acquir Immune Defic Syndr.* 2017;75(5):577–579. <https://doi.org/10.1097/QAI.0000000000001451>
24. Sinxadi PZ, Leger PD, McIlleron HM, et al. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. *Br J Clin Pharmacol.* 2015;80(1):146–156. <https://doi.org/10.1111/bcp.12590>
25. Sonderup MW, Maughan D, Gogela N, et al. Identification of a novel and severe pattern of Efavirenz drug-induced liver injury in South Africa. *AIDS.* 2016;30(9):1483–1485. <https://doi.org/10.1097/QAD.0000000000001084>
26. Jover F, Cuadrado JM, Roig P, Rodriguez M, Andreu L, Merino J. Efavirenz-associated gynecomastia: Report of five cases and review of the literature. *Breast J.* 2004;10(3):244–246.
27. Sikora MJ, Rae JM, Johnson MD, Desta Z. Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. *HIV Med.* 2010;11(9):603–607. <https://doi.org/10.1111/j.1468-1293.2010.00831.x>
28. Njuguna C, Swart A, Blockman M, et al. Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. *AIDS Res Ther.* 2016;13:40.
29. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two Phase III randomized trials. *AIDS.* 2013;27(6):939–950.
30. Behrens G, Rijnders B, Nelson M, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA \leq 100,000 copies/mL: Week 96 pooled ECHO/THRIVE subanalysis. *AIDS Patient Care STDS.* 2014;28(4):168–175. <https://doi.org/10.1089/apc.2013.0310>
31. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial. *Curr Med Res Opin.* 2005;21(10):1683–1692. <https://doi.org/10.1185/030079905X65439>
32. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis. *AIDS.* 2009;23(13):1679–1688.
33. Venter WDF, Moorhouse M, Sokhela S, et al. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): A randomised, open-label, phase 3, non-inferiority trial. *Lancet HIV.* 2019;6(7):e428–e437. [https://doi.org/10.1016/S2352-3018\(19\)30081-5](https://doi.org/10.1016/S2352-3018(19)30081-5)
34. Molina JM, Gallien S, Chaix ML, et al. Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: An open-label trial (ANRS 165 Darulight). *J Antimicrob Chemother.* 2018;73(8):2129–2136. <https://doi.org/10.1093/jac/dky181>
35. Insight Start Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med.* 2015;373(9):795–807.
36. Temprano Anrs Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med.* 2015;373(9):808–822.
37. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. *N Engl J Med.* 2016;375(9):830–839. <https://doi.org/10.1056/NEJMoa1600693>
38. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. *JAMA.* 2016;316(2):171–181.
39. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study. *Lancet.* 2019;393(10189):2428–2438.
40. Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: An international, prospective, observational, cohort study. *Lancet HIV.* 2018;5(8):e438–e447. [https://doi.org/10.1016/S2352-3018\(18\)30132-2](https://doi.org/10.1016/S2352-3018(18)30132-2)
41. O'Brien M, Markowitz M. Should we treat acute HIV infection? *Curr HIV/AIDS Rep.* 2012;9(2):101–110. <https://doi.org/10.1007/s11904-012-0113-0>
42. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. *J Infect Dis.* 2014;209(6): 931–939.

43. Crowell TA, Gebo KA, Blankson JN, et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. *J Infect Dis.* 2015;211(11):1692–1702. <https://doi.org/10.1093/infdis/jiu809>
44. Li JZ, Segal FP, Bosch RJ, et al. ART reduces T cell activation and immune exhaustion markers in HIV controllers. *Clin Infect Dis.* 2019;70:1636–1642.
45. Amanyire G, Semitala FC, Namusobya J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: A stepped-wedge cluster-randomised trial. *Lancet HIV.* 2016;3(11):e539–e548.
46. Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. *J Acquir Immune Defic Syndr.* 2017;74(1):44–51. <https://doi.org/10.1097/QAI.0000000000001134>
47. Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: The RapIT randomized controlled trial. *PLoS Med.* 2016;13(5):e1002015.
48. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: A systematic review and meta-analysis. *Ann Intern Med.* 2015;163(1):32–39.
49. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. *Clin Infect Dis.* 2011;52(11):1374–1383. <https://doi.org/10.1093/cid/cir230>
50. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. *N Engl J Med.* 2014;370(26):2487–2498.
51. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. *PLoS One.* 2009;4(5):e5575. <https://doi.org/10.1371/journal.pone.0005575>
52. Tucker JD, Bien CH, Easterbrook PJ, et al. Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: A systematic review. *AIDS.* 2014;28 Suppl 2:S151–S160.
53. Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: A multicentre cohort study. *Lancet Infect Dis.* 2018;18(2):188–197. [https://doi.org/10.1016/S1473-3099\(17\)30681-3](https://doi.org/10.1016/S1473-3099(17)30681-3)
54. Laprise C, De Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: Results from 12 years of observation. *Clin Infect Dis.* 2013;57(10):1489–1496. <https://doi.org/10.1093/cid/cit529>
55. Chimukangara B, Lessells RJ, Rhee SY, et al. Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naïve Adults in South Africa, 2000–2016: A pooled sequence analysis. *EClinicalMedicine.* 2019;9:26–34.
56. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. *AIDS.* 2003;17(7):963–969. <https://doi.org/10.1097/00002030-200305020-00004>
57. Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. *J Acquir Immune Defic Syndr.* 2010;55(4):451–459.
58. Tuboi SH, Pacheco AG, Harrison LH, et al. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. *J Acquir Immune Defic Syndr.* 2010;53(1):70–77. <https://doi.org/10.1097/QAI.0b013e3181c22d19>
59. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet.* 2004;364(9428):51–62.
60. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. *N Engl J Med.* 2014;371(3):234–247.
61. La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): A randomised, phase 3, non-inferiority study. *Lancet HIV.* 2016;3(6):e247–e258. [https://doi.org/10.1016/S2352-3018\(16\)30011-X](https://doi.org/10.1016/S2352-3018(16)30011-X)
62. Cohen K, Stewart A, Kengne AP, et al. A clinical prediction rule for protease inhibitor resistance in patients failing second-line antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2019;80(3):325–329.
63. Rhee SY, Grant PM, Tzou PL, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. *J Antimicrob Chemother.* 2019;74(11):3135–3149. <https://doi.org/10.1093/jac/dkz256>
64. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis. *Lancet Infect Dis.* 2018;18(3):346–355.

65. Lamorde M, Wang X, Neary M, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of Efavirenz 400 mg once daily during pregnancy and post-partum. *Clin Infect Dis*. 2018;67(5):785–790. <https://doi.org/10.1093/cid/ciy161>
66. Kaboggoza JP, Wang X, Neary M, et al. A lower dose of Efavirenz can be coadministered with Rifampicin and Isoniazid in tuberculosis patients. *Open Forum Infect Dis*. 2019;6(2):ofz035. <https://doi.org/10.1093/ofid/ofz035>
67. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet*. 2019;393(10167):143–155.
68. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. *Lancet*. 2018;391(10123):839–849.
69. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. *AIDS*. 2011;25(7):929–939.
70. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr*. 2010;53(3):323–332. <https://doi.org/10.1097/QAI.0b013e3181c990bf>
71. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. *AIDS*. 2006;20(5):711–718.
72. Boyd MA, Moore CL, Molina JM, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. *Lancet HIV*. 2015;2(2):e42–e51. [https://doi.org/10.1016/S2352-3018\(14\)00061-7](https://doi.org/10.1016/S2352-3018(14)00061-7)
73. Hill AM, Venter F. The unexpected success of NRTIs in second-line treatment. *Lancet Infect Dis*. 2018;18(1):3–5. [https://doi.org/10.1016/S1473-3099\(17\)30631-X](https://doi.org/10.1016/S1473-3099(17)30631-X)
74. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: Results of the ANRS 139 TRIO trial. *Clin Infect Dis*. 2009;49(9):1441–1449.
75. Moorhouse M, Maartens G, Venter WDF, et al. Third-line antiretroviral therapy program in the South African public sector: Cohort description and virological outcomes. *J Acquir Immune Defic Syndr*. 2019;80(1):73–78. <https://doi.org/10.1097/QAI.0000000000001883>
76. Grinsztejn B, Hughes MD, Ritz J, et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): A prospective strategy study. *Lancet HIV*. 2019;6(9):e588–e600.
77. Meintjes G, Dunn L, Coetsee M, et al. Third-line antiretroviral therapy in Africa: Effectiveness in a Southern African retrospective cohort study. *AIDS Res Ther*. 2015;12:39. <https://doi.org/10.1186/s12981-015-0081-8>
78. Gandhi RT, Tashima KT, Smeaton LM, et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS). *J Infect Dis*. 2019;221:1407–1415. <https://doi.org/10.1093/infdis/jiz281>
79. Stevens WS, Wallis CL, Sanne I, Venter F. Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? *J Acquir Immune Defic Syndr*. 2009;52(5):655–656.
80. Meintjes G, Brust JCM, Nuttall J, Maartens G. Management of active tuberculosis in adults with HIV. *Lancet HIV*. 2019;6(7):e463–e474. [https://doi.org/10.1016/S2352-3018\(19\)30154-7](https://doi.org/10.1016/S2352-3018(19)30154-7)
81. Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: A multicenter, noncomparative, open-label, randomized trial. *Clin Infect Dis*. 2019;70:549–556. <https://doi.org/10.2139/ssrn.3244943>
82. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. *Antimicrob Agents Chemother*. 2004;48(5):1553–1560.
83. Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron H. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. *PLoS One*. 2012;7(3):e32173.
84. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. *Cochrane Database Syst Rev*. 2007(4):CD005159. <https://doi.org/10.1002/14651858.CD005159.pub2>
85. Hennig S, Svensson EM, Niebecker R, et al. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. *J Antimicrob Chemother*. 2016;71(5):1330–1340. <https://doi.org/10.1093/jac/dkv470>

86. Bartlett JG, Gallant JE, Pham PA (eds). Medical management of HIV infection. 15th ed. Baltimore, MD: John Hopkins University Press, 2009–2010; 556 pp.
87. Gilbert DN, Moellering RC, Eliopoulos GM, et al. (eds). The Sanford Guide to antimicrobial therapy. 42nd ed. Sperryville, Virginia: Antimicrobial Therapy, Inc., 2012; 232 pp.
88. HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update. *Clin Infect Dis*. 2014;59(9):e96–e138.
89. Van Coppenhagen B, Duvenage HS. Prevalence of depression in people living with HIV and AIDS at the Kalafong Provincial Tertiary Hospital Antiretroviral Clinic. *S Afr J Psychiatr*. 2019;25:1175.
90. Jong E, Conradie F, Berhanu R, et al. Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB. *S Afr J HIV Med*. 2013;14(3):7. <https://doi.org/10.4102/sajhivmed.v14i3.63>
91. SEMDSA Type 2 Diabetes Guidelines Expert Committee. SEMDSA 2017 guidelines for the management of type 2 diabetes mellitus2017 [homepage on the Internet] [cited 2020 June 1]. Available from: <https://www.semdsa.org.za/images/647-4385-1-PB.pdf>
92. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: Proposed clinical case definitions. *Lancet Infect Dis*. 2010;10(11):791–802.
93. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. *Lancet Infect Dis*. 2008;8(8):516–523. [https://doi.org/10.1016/S1473-3099\(08\)70184-1](https://doi.org/10.1016/S1473-3099(08)70184-1)
94. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. *AIDS*. 2010;24(15):2381–2390. <https://doi.org/10.1097/QAD.0b013e32833dfc68>
95. Meintjes G, Sonderup MW. A practical approach to the diagnosis and management of paradoxical tuberculosis immune reconstitution inflammatory syndrome. *Contin Med Educ*. 2011;29(10):410–417.
96. Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. *N Engl J Med*. 2018;379(20): 1915–1925. <https://doi.org/10.1056/NEJMoa1800762>
97. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial. *Lancet*. 2014;384(9944):682–690. [https://doi.org/10.1016/S0140-6736\(14\)60162-8](https://doi.org/10.1016/S0140-6736(14)60162-8)
98. Group TAS, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med*. 2015;373(9):808–822. <https://doi.org/10.1056/NEJMoa1507198>
99. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: Individual participant data meta-analysis of observational studies. *PLoS Med*. 2011;8(1):e1000391. <https://doi.org/10.1371/journal.pmed.1000391>
100. Gupta A, Montepiedra G, Aaron L, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. *N Engl J Med*. 2019;381(14): 1333–1346. <https://doi.org/10.1056/NEJMoa1813060>
101. Kalk E, Heekes A, Mehta U, et al. Safety and effectiveness of isoniazid preventive therapy in HIV-positive pregnant women on art: An observational study using linked population data. *Clin Infect Dis*. 2020. <https://doi.org/10.1093/cid/ciz1224>



Website: www.sahivsoc.org



Telephone: +27 (0) 11 728 7365



Email: sahivcs@sahivcs.org

